A phase 2, multicentric study to assess the efficacy and safety of maribavir treatment in hematopoietic stem cell transplant (HSCT) recipients with cytomegalovirus (CMV) infection with a medical condition that contraindicate the administration of ganciclovir, valganciclovir or foscarnet and in those who discontinued first line preemptive therapy with ganciclovir, valganciclovir or foscarnet due to toxicity or intolerance.

开始日期2026-05-15

申办/合作机构-

CTIS2025-523487-21-00

/ Completed临床1期

An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Maribavir Tablets 200 mg, manufactured by Sun Pharmaceutical Industries Limited, India with LIVTENCITY® (Maribavir) Coated Tablets 200 mg, manufactured by: Catalent CTS, LLC Kansas City, United States of America, packed by: Takeda Ireland Limited Bray, Ireland, imported by: Takeda Pharma Ltda. Highway SP 340 S/N, km 133.5 Jaguariúna Administrative Building -SP CNPJ 60.397.775/0001-74 SAC: 0800 - 7710345, in healthy adult, human subjects under fasting condition.

开始日期2026-05-05

申办/合作机构

Sun Pharmaceutical Industries Ltd.

NCT07511127

/ Recruiting临床3期IIT

Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in Patients With Refractory Cytomegalovirus Infection Following Allo-HSCT: a Prospective, Multicenter, Randomized, Controlled Clinical Trial

To comparing the efficacy of different durations of Maribavir treatment regimens in patients suffering from refractory CMV infection after allo-HSCT.

开始日期2026-02-28

申办/合作机构

上海交通大学医学院附属瑞金医院

100 项与马立巴韦相关的临床结果

登录后查看更多信息

100 项与马立巴韦相关的转化医学

登录后查看更多信息

100 项与马立巴韦相关的专利（医药）

登录后查看更多信息

262

项与马立巴韦相关的文献（医药）

2026-12-31·JOURNAL OF MEDICAL ECONOMICS

Analysis of healthcare resource utilization before and after initiation of maribavir for cytomegalovirus treatment

Article

作者: Princic, Nicole ; Richards, Megan ; Bullano, Michael ; Kotton, Camille N. ; Gelone, Daniele K. ; Schultz, Bob G.

AIM:

This retrospective observational cohort study aimed to assess healthcare utilization (HCRU) and costs before and after initiation of treatment with maribavir using a United States (US) administrative claims database to further the understanding of the impact of maribavir in the real world setting.

METHODS:

Inovalon Databases were used to identify post-transplant patients with refractory (with or without resistant) CMV treated with maribavir between November 1, 2021 and March 31, 2024 (index = earliest treatment date). HCRU and costs were assessed during variable length periods both prior to and following initiation of maribavir. McNemar's tests were used to evaluate the statistical significance of differences for categorical variables and paired t-tests were used for continuous variables.

RESULTS:

There were 230 patients eligible for analysis. Compared with the pre-maribavir phase, after the initiation of maribavir there was a significant decrease in the utilization of all-cause acute care services, including inpatient hospital admissions (54.3% v. 30.9%; p < 0.001) and emergency room visits (47.0% v. 36.5%; p = 0.014). There was a significant decrease in the number of outpatient office visits per patient per month (PPPM) (2.33 v. 1.47; p < 0.001) as well as a decrease in the number of all outpatient pharmacy prescriptions PPPM (9.64 v. 7.69; p < 0.001). Total medical costs measured PPPM prior to maribavir initiation were $9,986 compared with $5,480 (p < 0.001) after initiation of maribavir.

CONCLUSIONS:

In real world practice, initiation of maribavir for the treatment of refractory or drug-resistant post-transplant CMV was associated with decreased acute care service utilization, reduced outpatient visits, and lower healthcare costs, resulting in meaningful benefits for both patients and healthcare systems. These reductions in healthcare utilization highlight maribavir's role in optimizing treatment strategies and improving the efficiency of CMV management.

2026-11-01·DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Case report:Maribavir for refractory CMV infection in 2 pediatric HSCT recipients

Article

作者: Chen, YiYu ; Jia, WenGuang ; Zhang, ZhiTing ; Huang, ShuWen ; OuYang, Heng ; Luo, JianMing ; He, YunYan

Cytomegalovirus (CMV) infection is one of the most prevalent severe complications post hematopoietic stem cell transplantation (HSCT), which significantly increases the morbidity and mortality risks among transplant recipients. Despite the continuous advancement of prevention and treatment strategies for CMV infection, refractory CMV infection remains a major clinical challenge in diagnosis and treatment, and this issue is even more prominent in pediatric patients due to the limited therapeutic options available. This paper reports the diagnosis and treatment of two pediatric cases with refractory CMV infection after HSCT. In Case 1, the child exhibited concurrent activation of CMV and Epstein-Barr virus (EBV) during the early post-transplant period, accompanied by severe hepatic impairment secondary to hepatic veno-occlusive disease. Salvage therapy with maribavir was administered following the ineffectiveness of ganciclovir, foscarnet and cellular immunotherapy, achieving effective control of the patient's condition. In Case 2, the child showed a poor response to monotherapy with ganciclovir and foscarnet, and subsequently progressed to CMV encephalitis. When conventional antiviral therapy failed and intolerable adverse reactions occurred, salvage therapy with a combination of maribavir and foscarnet was given, leading to a favorable clinical outcome. No definite adverse events associated with maribavir were observed in either of the two children during the treatment course. This study suggests that maribavir has potential therapeutic efficacy and favorable tolerability in the short-term clinical management of refractory CMV infection in pediatric patients post-HSCT, while its clinical application value in this population still needs to be further verified by studies with larger sample sizes.

2026-07-01·AJO international

Maribavir for cytomegalovirus retinitis: A case series and review of the literature

Article

作者: Thomas, Akshay S ; Kaisari, Eirini ; Kharouba, Rawan ; Goldstein, Debra A ; Janetos, Timothy M ; Emami, Seema ; Shughoury, Aumer

Objective:

Therapy for vision-threatening CMV retinitis is often limited by drug resistance or systemic toxicity. Maribavir, a novel UL97 kinase inhibitor that has been FDA-approved for refractory CMV viremia, is a potential alternative to traditional antiviral therapy but remains understudied for CMV retinitis. The objective of this series is to describe the clinical courses and outcomes of patients with CMV retinitis after initiation of maribavir therapy.

Design:

Retrospective case series.

Subjects:

Six patients (11 eyes) with CMV retinitis from two tertiary uveitis centers. All were immunocompromised due to chemotherapy, immunotherapy, or AIDS and were initially treated with standard therapy (systemic and/or intravitreal ganciclovir, valganciclovir, or foscarnet) before developing drug resistance, toxicity, or intolerance prompting a transition to maribavir as alternative therapy.

Intervention:

Oral maribavir 400 mg twice daily.

Main Outcome Measures:

Time to retinitis quiescence, visual acuity (VA), and adverse effects of therapy.

Results:

4/11 eyes had active retinitis upon initiation of maribavir and all achieved quiescence within 6 weeks. The remaining 7/11 eyes were already quiescent and remained so. VA remained stable or improved in all eyes. Notable clinical courses included (1) rapid decline in aqueous CMV titer and resolution of retinitis in a patient with multidrug-resistant CMV failing intravitreal ganciclovir/foscarnet; (2) a patient with UL54-resistant CMV and bilateral macula-involving retinitis rapidly achieving inactivity and preserved visual acuity on maribavir; and (3) successful substitution of maribavir in patients who were unable to continue conventional antiviral therapy due to drug-induced neutropenia or nephrotoxicity. Maribavir was generally well-tolerated, and only mild adverse effects were reported (dysgeusia, myalgia). Review of the literature identified 2 additional cases of patients with similar clinical courses achieving resolution of retinitis on maribavir.

Conclusions:

In this descriptive case series, patients with multidrug-resistant CMV retinitis or intolerance to traditional antiviral therapy were observed to achieve or maintain quiescence of retinitis following initiation of maribavir. These findings suggest maribavir as a potential novel systemic option for challenging cases of CMV retinitis. Prospective studies are necessary to further characterize the efficacy and safety of maribavir for the treatment of CMV retinitis, as well as optimal duration of therapy after quiescence.

154

项与马立巴韦相关的新闻（医药）

2026-06-12

·中华内科杂志

【标准与讨论】异基因造血干细胞移植受者巨细胞病毒感染临床管理指南（2025版）

点击标题下「蓝色微信名」可快速关注本文刊于：中华内科杂志,2026, 65(6): 523-537. 作者：国家血液内科专业医疗质量控制中心（筹）造血干细胞移植专业组通信作者：黄晓军，北京大学人民医院北京大学血液病研究所国家血液系统疾病临床医学研究中心血液肿瘤细胞和基因治疗北京市重点实验室，北京 100044 引用本文: 国家血液内科专业医疗质量控制中心（筹）造血干细胞移植专业组. 异基因造血干细胞移植受者巨细胞病毒感染临床管理指南（2025版）[J]. 中华内科杂志, 2026, 65(6): 523-537. DOI: 10.3760/cma.j.cn112138-20251023-00639. 摘要近年来，异基因造血干细胞移植（allo-HSCT）在治疗血液系统疾病中取得了显著进展，但巨细胞病毒（CMV）感染仍是移植后常见的并发症之一，严重影响患者的移植成功率和生存率。为了进一步规范中国allo-HSCT受者CMV感染的临床诊疗流程，由国家血液内科专业医疗质量控制中心（筹）造血干细胞移植专业组组织制订本指南。本指南基于中国allo-HSCT受者CMV感染的临床实践特点，结合国内外最新循证医学证据及指南共识，对CMV感染定义、流行病学、诊断标准和监测、CMV预防、抢先治疗以及难治耐药CMV管理进行了系统更新及补充，旨在为临床医生提供科学、实用的指导，以优化allo-HSCT受者CMV感染的管理，降低感染相关死亡率，提高患者长期生存质量。随着移植技术的不断进步和免疫抑制治疗的广泛应用，异基因造血干细胞移植（allogeneic hematopoietic stem cell transplantation，allo-HSCT）已成为多种血液系统疾病的重要治疗手段，2024年我国共报道了39 918例造血干细胞移植（HSCT），其中allo-HSCT约占70% ［ 1 ］。巨细胞病毒（cytomegalovirus，CMV）感染作为移植后常见的并发症之一，仍然是影响患者移植成功率、生存率和生活质量的关键因素。尽管近年来抗病毒药物的研发和诊断技术的进步显著提升了CMV感染的临床管理，但难治性和耐药性感染等问题仍是临床面临的重大挑战。为进一步提高CMV感染的诊疗水平，特制订此指南供国内临床医生参考。本次指南制订工作由国家血液内科专业医疗质量控制中心（筹）造血干细胞移植专业组牵头，在组织架构上由造血干细胞移植领域的权威专家组成指南制订小组和指南审稿小组，其中既有专注于免疫低下感染尤其是病毒感染的专家，也有以循证医学和方法学见长的专家。整个项目由黄晓军教授牵头组织实施。工作组参考《异基因造血干细胞移植患者巨细胞病毒感染管理中国专家共识（2022年版）》［ 2 ］，通过文献调研、专家咨询及前期共识实施反馈，确定指南纳入的临床问题，按CMV感染管理的自然病程分模块梳理，涵盖定义、流行病学、诊断与监测、预防策略、CMV治疗、难治/耐药感染管理、嵌合抗原受体T细胞疗法（chimeric antigen receptor T-cell therapy，CAR-T）/双特异性抗体疗法七大主题。工作组全面检索了2015年1月至2025年1月国内外权威数据库，涵盖PubMed、Embase、Medline、万方知识数据服务平台以及中国知网等有关allo-HSCT受者巨细胞病毒感染相关研究。依据牛津循证医学中心证据分级体系［ 3 ］对文献质量进行评估与分级（表1 ）。优先纳入系统评价与Meta分析、随机对照试验、前瞻性队列研究，排除标准包括：证据级别较低且对核心临床问题贡献有限的研究（如单纯机制研究、专家观点性文章）；方法学质量较差或存在明显偏倚、不一致性及高异质性的研究。推荐强度在证据等级基础上，综合考虑临床可行性及中国人群特点进行适当调整。通过两轮专家共识会议，系统评价小组汇报各主题模块证据汇总结果，专家组审议讨论，对推荐意见进行多轮讨论投票达成共识。指南初稿完成后提交指南审稿小组的独立外部专家进行评审，根据评审意见修改完善。所有指南参与人员均填写利益冲突声明表，由指导小组统一管理。一、CMV感染的定义 CMV感染定义为在任何体液或组织样本中检测到病毒、病毒蛋白（抗原）或核酸，包括以下类型［ 2 ， 4 ］。 1.原发性CMV感染：首次发生的CMV感染。 2.CMV再激活：内源性潜伏CMV所导致的感染。 3.CMV病毒血症：在血标本中分离出病毒或检出病毒蛋白/核酸。包括：（1）CMV-DNA血症：在血标本中检测到病毒DNA；（2）CMV抗原血症：在外周血白细胞中检测到病毒PP65抗原。 4.CMV病：有临床症状和体征的CMV感染。包括：（1）CMV综合征：在CMV血症的基础上出现发热、乏力、骨髓抑制、转氨酶升高等非特异性症状，并排除CMV终末器官疾病；（2）CMV终末器官疾病：CMV侵犯组织器官并导致相应症状和体征。 5.有临床意义的CMV感染（clinically significant cytomegalovirus infection，cs-CMVi）：需要启动抗病毒抢先治疗的CMV病毒血症或发生CMV病。 6.难治性CMV感染：在接受至少2周合理抗CMV治疗后，CMV病毒血症仍持续存在（病毒载量下降≤1 log 10）或进展（同一实验室/检测试剂检测的同种血标本中病毒载量较峰值升高>1 log 10）。 7.难治性CMV病：在接受至少2周的合理抗CMV治疗后，体征和症状恶化或进展为CMV病（之前未诊断为CMV病），或CMV病的症状、体征无改善。 8.耐药性CMV感染：在难治性CMV感染诊断基础上，存在病毒基因突变，导致CMV对一种或多种抗病毒药物的敏感性降低。 9.CMV DNA载量波动（CMV DNA Blips）：在接受来特莫韦（letermovir，LMV）预防的患者中，单次检测到CMV DNA，通常病毒载量较低，且该结果前后相邻的检测结果均为阴性或低于检测下限，可能代表无活性的病毒复制或游离病毒DNA的自然降解。二、流行病学与危害抢先治疗时代，中国allo-HSCT成人患者CMV感染发生率为18%~85%，其中单倍体移植CMV感染发生率为58.8%~83%、脐带血移植为70%~85% ［ 2 ， 5 ］，难治性CMV感染约48% ［ 6 ］。儿童allo-HSCT受者CMV感染发生率为40.0%~60.6% ［ 7 , 8 ］。对于单倍体移植受者，采用抗胸腺细胞球蛋白（anti-thymocyte globulin，ATG）方案与国外常用的后置环磷酰胺（post- transplant cyclophosphamide，Ptcy）方案的CMV感染发生率差异无统计学意义（ATG组及Ptcy组分别为46%和50%）［ 9 ］。近年来，在CMV预防策略广泛应用的背景下我国移植受者CMV感染率大大降低，如单倍体移植人群移植后100 d的CMV感染发生率由58.8%下降至17.6% ［ 5 ］、65.4%下降至4.3% ［ 10 ］，脐带血移植人群从73.4%降至25.6% ［ 11 ］，再生障碍性贫血人群从77.4%下降至26.5% ［ 12 ］。儿童患者在接受CMV预防后，CMV感染发生率从60.2%显著降低至27.8% ［ 13 ］，其中单倍体和脐血移植儿童CMV感染发生率从56%降低至13.4% ［ 14 ］。值得注意的是，当100 d的CMV预防结束后，在高危人群中，如脐带血移植人群180 d迟发性CMV感染发生率为31.0% ［ 11 ］，单倍体移植人群迟发性CMV感染发生率为26.1% ［ 10 ］，提示需关注迟发性CMV感染的发生。在开展CMV预防后，部分中心观察到基于ATG预防移植物抗宿主病（graft-versus-host disease，GVHD）的移植方案中，EB病毒感染［ 15 ］或移植后淋巴增殖性疾病发生率增加［ 16 , 17 ］，但也有中心报道CMV预防对EB病毒再激活无影响［ 10 ， 18 , 19 ］。 CMV感染可通过直接和间接作用给移植患者带来健康危害。新发感染或再激活可引发CMV血症或CMV终末器官疾病等直接效应［ 20 , 21 ］。此外，CMV感染还会带来间接效应，与移植功能不良、继发细菌感染、侵袭性真菌感染、肾功能不全、出血性膀胱炎、急性GVHD、再住院、非复发死亡率和总体死亡率上升相关［ 22 , 23 , 24 ］。三、CMV感染的诊断与监测（一）allo-HSCT后CMV感染的诊断方法和样本选择实时荧光定量PCR是目前最常用、最便捷的检测方法［ 25 ］。目前，我国CMV感染诊断折点尚未统一，主要由于不同移植人群和移植类型感染风险差异、CMV检测方法多样性和缺乏统一校准等原因［ 26 , 27 , 28 ］。CMV DNA定量的国际单位（IU）和拷贝数（copies）的转换不是固定的，全血样本的平均转换因子（copies/ml转换为IU/ml）为0.64（范围0.21~1.17），血浆样本为0.82（范围0.39~2.2）［ 29 ］，依赖于具体实验室的检测方法和标准品。 PCR检测样本主要包括全血和血浆。研究发现，全血和血浆CMV DNA检出率相似［ 30 , 31 ］，但鉴于CMV DNA载量在全血和血浆中数值差异较大，所以建议临床实践中使用同一种类型的样本进行监测，为后续治疗决策的制定提供连续、准确的依据［ 32 ］。推荐意见： 1.推荐使用实时定量PCR作为HSCT受者CMV感染监测和诊断的一线方法（推荐强度B，证据等级2b） 2.由于移植类型和诊断检测方法等不同，各中心应根据各自方法学建立启动阈值（推荐强度B，证据等级2c） 3.血浆或全血均可作为诊断标本（推荐强度B，证据等级2b）。对同一患者的CMV DNA病毒载量监测应使用相同的DNA提取方法、实时定量PCR检测方法及同类血标本（推荐强度B，证据等级2b）（二）allo-HSCT后CMV病的诊断方法和样本选择 CMV病的诊断需结合临床症状及微生物学证据，组织病理学是确诊CMV病的金标准［ 4 ， 33 ］，诊断标准详见表2 。（三）allo-HSCT CMV感染的监测大部分CMV感染在移植后100 d内发生［ 34 ］，这个时期每周1~2次CMV监测可及时干预，有效降低CMV感染的风险，改善患者的预后［ 2 ］。研究表明，部分患者在移植后第100天结束CMV预防后，仍可能发生迟发性CMV感染，通常发生于停药后的1~2个月内［ 11 ， 35 ］，因此CMV预防结束后应继续监测CMV至移植后至少6个月［ 36 ］。推荐意见：无论是否接受CMV预防，HSCT后每周进行1~2次CMV监测，持续至移植后100 d（推荐强度B，证据等级2b）。100 d后对仍然处于免疫抑制状态患者应延长CMV监测至移植后至少6个月或免疫抑制状态解除（推荐强度B，证据等级2b）四、CMV预防（一）非药物预防移植前供受者血清学检测及供者选择对预防CMV感染至关重要。相较于供受者血清学双阴性（D-/R-）人群，当供者和/或受者存在血清学阳性状态时，移植后总体生存率显著降低［ 37 ］。对CMV血清学阴性的受者（R-）选择CMV血清学阴性的供者（D-），可降低非复发死亡风险［ 38 ］。对于CMV血清学阳性受者（R+），选择血清学阴性供者（D-）移植将导致多重不良临床结局，CMV特异性免疫重建延迟、病毒激活次数增加、CMV病毒载量升高、迟发性CMV感染、难治性CMV感染、CMV病等发生率均明显高于选择CMV血清学阳性供者（D+）移植，提示对于CMV血清阳性受者应优先考虑CMV血清学阳性供者［ 39 ］。我国CMV血清学阳性人群比例超过90%，临床实践中供受者配对以D+/R+组合最为常见［ 40 , 41 ］。为减少输血传播的CMV感染风险，通常使用去白细胞或CMV血清学阴性的血制品［ 42 , 43 ］。目前关于免疫球蛋白在预防CMV感染中的效果仍有争议。一项系统综述评估了免疫球蛋白用于预防CMV感染对HSCT受者临床结局的影响，结果显示，免疫球蛋白对CMV感染发生率、总体生存率无显著影响［ 44 ］。推荐意见： 1.推荐所有供者和受者移植前评估CMV血清学（CMV IgG）水平（推荐强度B，证据等级2b） 2.尽可能选择CMV血清学一致的供受者组合：对于血清学阴性受者（R-），尽可能选择血清学阴性供者（D-）；对于血清学阳性受者（R+），选择血清学阳性供者（D+）（推荐强度B，证据等级2b） 3.建议优先选择去白细胞处理的血制品或CMV血清学检测阴性的血制品进行输注（推荐强度B，证据等级2b） 4.由于获益证据有限，不推荐常规使用免疫球蛋白或CMV特异性免疫球蛋白（CMV-specific intravenous immunoglobulin，CMV-IVIG）进行预防（推荐强度A，证据等级1a）（二）药物预防 1.药物选择随着LMV的应用，我国已有多项真实世界研究验证了LMV在单倍体移植［ 5 ， 45 ］、脐带血移植［ 11 ］、再生障碍性贫血［ 12 ］、全相合移植［ 46 ］中的预防疗效和安全性。中国一项上市后3期研究显示，LMV预防的有效性与全球3期研究结果［ 47 ］相当，患者在移植后第14周和24周cs-CMVi发生率分别为7.1%和32.7%，第24周未出现CMV病［ 48 ］。一项2b期临床试验结果显示，LMV用于6个月及以上且体重≥6 kg的allo-HSCT受者的CMV预防，其体内暴露量与成人相当，cs-CMVi发生率与成人3期研究结果相似（24%比37.5%）［ 49 ］。我国3项单中心真实世界研究证实，LMV可显著降低儿童allo-HSCT、单倍体移植和脐血移植后CMV感染的发生，且安全性良好［ 13 , 14 ， 50 ］。LMV已于2025年6月在国内获批用于儿童allo-HSCT后CMV预防，同时其新增儿童剂型［来特莫韦片（Ⅱ）］也于9月获批（儿童剂量见表3 ）［ 51 ］。需要注意的是，接受LMV预防过程中出现CMV DNA blips时，血浆中的CMV DNA载量通常不超过1 500 IU/ml，或全血中不超过10 000 IU/ml ［ 52 , 53 , 54 ］，该现象不表示发生突破性感染或出现LMV耐药。 2.药物预防启动时机及疗程随机对照研究显示，移植后0~28 d（中位时间9 d）内启动CMV预防可有效降低移植后CMV感染发生率［ 47 ］。国外多中心前瞻性研究结果证明，移植后较早（0~1 d）开始LMV预防的患者与较晚预防（2~27 d）的患者相比，至少一次CMV血症的比例更低（14.8%比45.8%， P=0.010 7）［ 52 ］。我国单中心研究同样发现在移植后0~14 d内启动LMV预防的CMV感染发生率低于移植后14 d以后启动预防的CMV感染发生率（7.44%比23.91%， P=0.005）［ 55 ］。我国另一项多中心研究进一步证实，与晚启动LMV预防（移植后14 d以后）相比，移植后1 d启动LMV预防可显著降低移植后100 d的cs-CMVi率（5.1%比30.6%， P<0.000 1），同时早启动组患者移植后180 d的cs-CMVi发生率也显著低于晚启动组（13.3%比35.8 %， P<0.000 1），均提示移植后尽早启动LMV预防的获益［ 56 ］。对于所有CMV血清学阳性成人受者，预防持续至移植后100 d均有显著临床获益。但3期研究显示约20%的高危患者在停止LMV预防后发生迟发性CMV感染［ 47 ］，特别是单倍体移植人群高达47% ［ 57 ］。研究提示如人类白细胞抗原（human leukocyte antigen，HLA）不匹配移植、单倍体移植、脐带血移植、供者血清学为IgG阴性、移植后100 d内发生过CMV感染、淋巴细胞减少、急慢性GVHD、使用大剂量糖皮质激素（泼尼松≥1 mg·kg -1·d -1）等均为迟发性CMV感染的高危因素［ 35 ， 58 , 59 , 60 , 61 ］。2024年一项针对高危人群［包括单倍体移植、脐带血移植、HLA不匹配移植、接受ATG或阿仑单抗的体外去T细胞移植、移植后发生GVHD或使用大剂量糖皮质激素治疗（泼尼松大于1 mg·kg -1·d -1）等］的随机对照研究显示，将LMV预防疗程从移植后100 d延长至200 d，可使cs-CMVi发生率由19%降低至3%，且安全性无显著差异［ 36 ］。真实世界研究也证实，对于移植后发生GVHD ［ 62 ］、单倍体移植［ 63 ］、脐带血移植［ 64 ］等人群，延长CMV预防疗程可显著降低迟发性CMV感染的发生率。我国学者研究表明，对于（接受来自CMV血清阳性半相合供体、大量糖皮质激素、多种免疫抑制剂、患二级以上GVHD或既往CMV感染史）的儿童，LMV使用>100 d 组移植后24周CMV再激活比例显著低于LMV使用≤100 d组（5.89%比11.10%， P=0.009）［ 50 ］。LMV于2025年8月获批预防成人迟发性CMV感染至移植后200 d。监测CMV特异性细胞免疫（CMV cell- mediatedimmunity，CMV CMI）包括对CD4 +/CD8 +T细胞或对细胞因子（如γ-干扰素）的评估来指导CMV预防疗程仍在探索阶段。我国学者研究发现，相比较于预防100 d组，CMV-CMI指导预防组中位预防时间为122 d，1年累积迟发性CMV感染发生率显著降低（9.7%比24.8%， P=0.019），同时CMV-CMI指导预防组患者总生存率及非复发生存率均有提高［ 65 ］。 3.二级预防对于一些CMV感染高风险人群，有可能在CMV治疗结束后再次发生CMV激活，应考虑进行二级预防以避免复发。基于国外现有证据［ 66 , 67 , 68 , 69 , 70 ］，LMV在二级预防中表现出良好的安全性和有效性，可作为二级预防的新选择。我国目前尚无LMV用于二级预防的研究报道，期待未来更多经验的积累。二级预防的启动时机和疗程应根据患者的具体情况而定。推荐意见： 1.对于CMV感染的高危患者（如CMV IgG阳性、单倍体移植、脐带血移植、HLA不匹配移植、接受ATG预处理、淋巴细胞恢复慢等），建议移植后启动LMV进行初级预防至移植后100 d（推荐强度A，证据等级1b） 2.应尽早启动LMV预防（推荐强度B，证据等级2b），最迟不晚于移植后28 d启动，以预防早期CMV再激活（推荐强度A，证据等级1b） 3.有迟发性CMV感染风险的高危患者［如移植后发生急慢性GVHD或使用大剂量糖皮质激素（泼尼松大于1 mg·kg -1·d -1）、脐带血移植、供受者血清学状态为D-/R+、CMV感染史、CMV特异性免疫重建差等］，建议延长预防至移植后200 d或根据患者免疫状态酌情延长（推荐强度A，证据等级1b）。有条件的中心可结合CMV-CMI指导预防疗程（推荐强度B，证据等级2b） 4.对于6个月及以上的儿童CMV感染高危患者（如CMV IgG阳性、单倍体移植、脐带血移植、HLA不匹配移植、接受ATG预处理等），建议移植后启动LMV进行初级预防至移植后100 d，或根据患儿免疫状态酌情延长（推荐强度B，证据等级2b） 5.CMV预防期间血浆或全血样本中出现单次低水平DNA阳性，除非出现连续的阳性样本且病毒载量呈上升趋势，否则不建议中断LMV预防（推荐强度B，证据等级2b）五、CMV治疗策略（一）CMV抢先治疗 CMV抢先治疗是为预防CMV病的发生而实施的针对CMV病毒血症的治疗。目前更昔洛韦是抢先治疗的一线用药，具有强效的抗CMV活性，通常静脉给药，但需注意更昔洛韦引起的骨髓毒性［ 71 ］。一项随机临床试验表明，膦甲酸钠与更昔洛韦疗效相当，由于其骨髓毒性相对较小，建议中性粒细胞减少症或血小板减少症患者使用。膦甲酸钠的常见副作用包括肾毒性和电解质紊乱，因此建议每周至少进行2次肾功能和离子图监测［ 72 ］。缬更昔洛韦也可考虑作为一线治疗的替代选择，治疗有效率为56.0%~91.4% ［ 73 , 74 ］，不适用于口服吸收困难者。马立巴韦在所有一线治疗药物不耐受患者中也表现出一定疗效，一项随机非劣效性对照试验中，马立巴韦与缬更昔洛韦分别给药8周作为CMV抢先治疗的一线方案，结果显示马立巴韦未达到非劣效性（病毒血症清除率：缬更昔洛韦为77.4%，马立巴韦为69.6%）［ 75 ］。因马立巴韦未获批抢先治疗一线适应证，仅建议用于中性粒细胞减少或肾功能不全患者。当进展为难治性CMV血症或出现耐药时，应更换另一类未使用的一线药物（更昔洛韦/缬更昔洛韦或膦甲酸钠），或选择马立巴韦作为二线治疗。由于肾毒性发生率较高、药物可及性较差，西多福韦仅被视为三线治疗选择［ 27 ］。除以上药物治疗外，过继输注CMV特异性细胞毒性T细胞（cytomegalovirus-specific cytotoxic T lymphocyte，CMV-CTLs）和静脉注射CMV-IVIG也成为近年来抢先治疗CMV感染的新选择。与更昔洛韦组相比，CMV-CTLs联合更昔洛韦组的持续性CMV感染、迟发性CMV感染显著降低［ 26 ］；CMV-IVIG联合传统抗病毒药物可加速CMV-DNA血症转阴和外周CMV清除，并提高2周缓解率，在使用高剂量ATG（兔-ATG>6 mg/kg体重，猪-ATG>40 mg/kg体重）预处理的单倍体移植人群效果更为明显［ 76 ］。然而，目前CMV-CTLs和CMV-IVIG均尚未纳入常规临床治疗方案。抢先治疗的停药时机主要基于病毒载量的检测结果和患者的临床表现。我国多数中心采用连续2次CMV-DNA检测阴性或连续2次检测均低于抢先治疗启动阈值作为停药指标［ 77 , 78 , 79 ］。推荐意见： 1.更昔洛韦或膦甲酸钠可作为抢先治疗的一线用药，用药期间需要密切监测患者肾功能、血细胞状态及电解质状态（推荐强度A，证据等级1b）。缬更昔洛韦可作为一线替代，但不适用于口服吸收困难的患者（推荐强度B，证据等级2b） 2.马立巴韦可作为（缬）更昔洛韦或膦甲酸钠不耐受患者的替代选择（推荐强度B，证据等级2b） 3.联合使用CMV-CTLs或CMV-IVIG可能提供额外的疗效及安全优势（推荐强度C，证据等级4） 4.建议连续2次检测结果均为阴性或低于抢先治疗阈值时，可作为停药的标准（推荐强度B，证据等级2b）（二）CMV病的治疗 1.CMV肺炎：更昔洛韦单药治疗作为一线选择。当患者对更昔洛韦不耐受时，膦甲酸钠可作为替代方案［ 80 , 81 ］。也有学者采用更昔洛韦联合膦甲酸钠作为二线治疗方案［ 81 , 82 , 83 ］。我国有研究报道应用糖皮质激素在晚发型重症肺炎治疗中可以明显改善预后，但用法用量还需要再探索［ 84 ］。对于重症CMV肺炎，如果可能，可同时减少免疫抑制剂的剂量。另外，研究表明抗病毒治疗中加入静脉免疫球蛋白没有改善总体死亡率［ 82 ］。 2.CMV视网膜炎（CMV renitis，CMVR）：主要临床症状为视力模糊、飞蚊症、视野缺陷、视网膜局灶性出血伴黄白色颗粒（“披萨派”外观）等［ 85 ］。我国最新研究发现从HSCT至诊断CMVR的中位时间为148（119，196）d，合并CMV血症发生率仅26.3%，因此移植后早期（如移植后3~6个月）对患者进行定期眼底检查，以尽早发现病变，预防严重的视力丧失［ 86 ］。若一旦出现CMV血症，建议立即进行眼底检查。CMVR通常采用玻璃体腔内注射更昔洛韦，联合全身抗病毒药物如更昔洛韦、缬更昔洛韦、膦甲酸钠的治疗方案［ 20 ， 87 ］。建议请眼科医生对患者进行评估和局部治疗操作。 3.CMV胃肠炎：更昔洛韦可作为CMV胃肠炎一线治疗，膦甲酸钠或两者联合可用于更昔洛韦耐药患者，西多福韦可用于对膦甲酸无反应或不耐受的患者［ 88 ］。虽然在肠道活检标本中使用PCR检测CMV的敏感性和特异性与免疫组织化学检测相当［ 89 ］，然而由于缺乏标准化，有上消化道和/或下消化道症状以及PCR检测出组织中CMV，而肉眼未见黏膜病变，仅为拟诊CMV胃肠炎的诊断依据。粪便标本不能作为诊断依据。 4.CMV脑炎：最常采用更昔洛韦联合膦甲酸钠治疗，其次为更昔洛韦或膦甲酸钠单药治疗［ 90 , 91 , 92 ］。对于难治或耐药性CMV脑炎，CMV-CTLs治疗显示出良好的抗病毒效果，能够有效清除脑脊液中的病毒并改善患者神经功能［ 93 ］。如果可能，可同时减少免疫抑制剂的剂量。 5.其他类型CMV病：由于研究较少，可参照CMV肺炎治疗。除抗病毒药物治疗外，CMV特异性过继细胞疗法可能是安全有效的CMV病治疗的替代方案［ 94 ］，对一线抗病毒治疗耐药的CMV病可考虑使用［ 95 ］。此外，临床试验显示T细胞受体（TCR）工程化T细胞疗法也是具有前景的治疗方法，通过基因工程技术将特异性识别CMV抗原的TCR基因导入T细胞中，使其能够精准识别并清除CMV感染的细胞［ 96 ］。推荐意见： 1.CMV肺炎：静脉滴注更昔洛韦治疗作为一线方案（推荐强度A，证据等级2b），膦甲酸钠作为更昔洛韦不耐受时的替代（推荐强度B，证据等级2b），静脉注射免疫球蛋白可考虑作为联合治疗方案（推荐强度D，证据级别5），对于晚发重症肺炎可考虑联合糖皮质激素（推荐强度D，证据级别5） 2.CMV视网膜炎：玻璃体内注射更昔洛韦联合全身抗CMV治疗作为一线方案，并请有经验的眼科医师进行评估及局部治疗（推荐强度B，证据等级2b）。移植后早期眼底检查可及早诊断并治疗CMV视网膜炎，预防严重视力丧失（推荐强度B，证据等级2b） 3.CMV脑炎：联合更昔洛韦和膦甲酸钠作为一线方案治疗CMV脑炎（推荐强度C，证据等级4） 4.CMV胃肠炎：更昔洛韦可作为一线方案，膦甲酸钠或两者联合可用于更昔洛韦耐药（推荐强度B，证据等级2b），西多福韦可作为对膦甲酸无反应或不耐受的替代（推荐强度C，证据等级4）六、难治/耐药CMV感染治疗 1.药物选择当患者被诊断为难治性或耐药性CMV感染/病时，需考虑更换治疗药物。若患者同时伴有严重的全血细胞减少，建议优先选择膦甲酸钠或西多福韦［ 6 ， 95 ］。对于无法耐受骨髓抑制和肾损伤的患者，可考虑口服马立巴韦。目前马立巴韦已在中国获批上市，一项随机对照研究显示，马立巴韦治疗难治性及耐药性CMV感染，8周后病毒清除率显著高于传统治疗（55.7%比23.9%， P<0.001）。然而，长期使用或存在耐药菌株时，需警惕马立巴韦耐药风险的增加。此外，由于马立巴韦无法透过血脑屏障和血眼屏障，对中枢神经系统（包括视网膜）的CMV病患者无效［ 97 ］。除了单药治疗外，也可考虑联合治疗。有病例报道显示更昔洛韦联合半剂量膦甲酸钠可用于治疗难治性及耐药性CMV感染［ 90 ］；另一项小型研究提示更昔洛韦与膦甲酸钠联合治疗显著降低移植相关死亡率（13%比47%， P=0.02）［ 98 ］；马立巴韦与膦甲酸钠联合治疗表现出较好的病毒清除率［ 99 , 100 ］。然而，一项纳入242例患者的中国研究显示，更昔洛韦和膦甲酸钠联合治疗与单药治疗在总死亡率（92.0%比87.1%， P=0.543）及无病生存率（90.3%比85.7%， P=0.665）方面差异无统计学意义［ 77 ］。此外，由于更昔洛韦（或缬更昔洛韦）与马立巴韦在作用机制上可能存在拮抗，不建议二者联合使用［ 101 ］。鉴于联合用药可能增加毒性且疗效尚待进一步验证，仅作为难治或耐药CMV感染/病的备选方案。此外，如果可能，可同时减少免疫抑制剂的剂量。 2.过继CMV特异性T细胞在难治/耐药CMV感染中的应用近年来我国在CMV-CTLs治疗难治/耐药CMV感染领域取得了显著进展。一项纳入190例单倍体移植患者的研究中，采用供者来源的CMV-CTLs作为难治性CMV感染或疾病的挽救性治疗，结果显示首次输注CMV-CTLs后第1、4、6周累积完全缓解率分别为37.2%、74.5%和86.9% ［ 102 ］。随后，多项研究证实第三方来源CMV-CTLs与供者来源的CMV-CTLs完全缓解率相似［ 103 , 104 ］。此外，一项1期研究显示，第三方来源的CMV-CTLs在脐带血移植后难治性CMV感染治疗中，6个月内80%（8/10）患者实现持久病毒学清除［ 105 ］。儿童相关两项回顾性单中心研究（10例和29例）显示疗效与成人研究类似［ 7 ， 106 ］。CMV CTLs主要不良反应包括细胞因子释放综合征、轻度发热及GVHD等。目前CMV-CTLs在我国尚未上市，不作为常规治疗手段。推荐意见： 1.马立巴韦作为难治/耐药CMV感染的一线治疗选择（推荐强度A，证据等级1b），但对于累及中枢神经系统或眼部的CMV病，不推荐使用马立巴韦（推荐强度B，证据等级2b） 2.膦甲酸钠（推荐强度B，证据等级2c）或西多福韦（推荐强度C，证据等级4）可作为替代治疗选择（适用于肾功能正常患者），但需关注药物的耐受性 3.更昔洛韦联合膦甲酸钠（推荐强度C，证据等级4）或马立巴韦联合膦甲酸钠治疗也可作为替代方案（推荐强度C，证据等级4），但不建议更昔洛韦（或缬更昔洛韦）与马立巴韦联合治疗（推荐强度B，证据等级2c） 4.CMV-CTLs可作为难治/耐药CMV感染的辅助性治疗手段（推荐强度C，证据等级4） 3.难治/耐药CMV感染的基因检测抗CMV药物的耐药在HSCT受者中并不常见，通常在治疗几周后出现，以UL97基因突变为主，UL54基因突变相对少见。常见耐药位点及药物选择见表4 ［ 107 , 108 , 109 ］。推荐意见： 1.当怀疑出现难治/耐药CMV感染时，有条件的中心可进行抗病毒药物耐药基因检测，检测位点应包括UL97、UL54、UL56（推荐强度B，证据级别2b） 2. 在等待基因检测结果期间，应先调整抗病毒治疗方案（推荐强度B，证据级别2b）七、CAR-T/双特异性抗体治疗血液病患者的CMV管理多项研究显示，在接受CAR-T治疗后第1个月内，CMV感染率为17%~56% ［ 110 , 111 , 112 , 113 , 114 , 115 , 116 ］。CMV激活多发生在CAR-T治疗后14~21 d ［ 110 , 111 , 112 , 113 , 114 , 115 ］。CAR-T治疗患者CMV激活风险因素包括：CMV DNA血症史、3~4级细胞因子释放综合征、同时使用两种及以上免疫抑制剂［ 111 ， 115 , 116 ］，免疫效应细胞相关神经毒性综合征［ 117 ］等。双特异性抗体治疗后CMV激活的危险因素与CAR-T治疗患者类似，对于连续接受双特异性抗体和CAR-T治疗的患者，风险可能进一步增加［ 118 ］。推荐意见：对于有CMV风险因素的CAR-T或双特异性抗体治疗血液病患者在治疗后2~6周积极进行CMV监测（推荐强度B，证据级别2b），如有必要建议早期进行积极的预防干预措施（推荐强度C，证据级别4）八、展望本指南基于allo-HSCT后CMV感染的临床实践和循证医学证据制订，并将随着新型抗病毒药物研发、免疫及监测技术的进步持续更新。未来，二次移植、JAK抑制剂（如芦可替尼）及CAR-T疗法等因素对CMV感染风险的影响需进一步探索。尿液CMV-DNA检测、粪便游离DNA检测、宏基因组二代测序技术等方法在诊断中的作用仍需更多验证。而CMV免疫监测的不断完善，也将为个体化治疗的发展提供有力支持。期待通过多中心协作，积累高质量研究数据，为CMV感染管理提供坚实依据，最终改善allo-HSCT受者的长期预后和生活质量。执笔：许兰平；张晓辉参与指南制订和讨论的专家（排名不分先后）：黄晓军（北京大学人民医院北京大学血液病研究所）、孙于谦（北京大学人民医院北京大学血液病研究所）、王昱（北京大学人民医院北京大学血液病研究所）、许兰平（北京大学人民医院北京大学血液病研究所）、张晓辉（北京大学人民医院北京大学血液病研究所）、程翼飞（北京大学人民医院北京大学血液病研究所）、陆佩华（北京陆道培血液病医院）、胡建达（福建医科大学附属第二医院血液科）、李乃农（福建医科大学附属协和医院血液科）、赖永榕（广西医科大学附属第一医院血液科）、刘容容（广西医科大学附属第一医院血液科）、宋永平（郑州大学第一附属医院血液科）、符粤文（河南省肿瘤医院血液科）、夏凌辉（华中科技大学同济医学院附属协和医院血液科）、张义成（华中科技大学同济医学院附属同济医院血液科）、陈心传（四川大学华西医院血液科）、曹伟杰（郑州大学第一附属医院血液科）、刘传芳（齐鲁大学齐鲁医院血液科）、徐雅靖（中南大学湘雅医院血液科）、贺鹏程（西安交通大学第一附属医院血液科）、高素君（吉林大学第一医院血液科）、王顺清（广州市第一人民医院血液科）、王三斌（解放军第九二〇医院血液科）、胡亮钉（解放军总医院血液科）、刘代红（解放军总医院血液科）、张曦（陆军大学第二附属医院血液病医学中心）、刘启发（南方医科大学南方医院血液科）、宣丽（南方医科大学南方医院血液科）、陈静（上海交通大学医学院附属上海儿童医学中心血液科）、罗成娟（上海交通大学医学院附属上海儿童医学中心血液科）、胡炯（上海交通大学医学院附属瑞金医院血液科）、胡晓霞（上海交通大学医学院附属瑞金医院血液科）、王昭（首都医科大学附属北京友谊医院血液科）、唐晓文（苏州大学附属第一医院血液科）、吴德沛（苏州大学附属第一医院血液科）、江明（新疆医科大学附属第一医院血液科）、袁海龙（新疆医科大学附属第一医院血液科）、闫志凌（徐州医科大学附属医院血液科）、黄河（浙江大学医学院附属第一医院血液科）、罗依（浙江大学医学院附属第一医院血液科）、朱小玉（中国科学技术大学第一医院血液科）、姜尔烈（中国医学科学院血液病医院中国医学科学院血液学研究所）利益冲突所有作者声明无利益冲突参考文献（略）编辑：赵景辉初审：赵景辉终审：刘雪松

基因疗法

2026-06-10

·北京医学感染与传染研究

抗菌化疗杂志81卷 1-6期

Journal of Antimicrobial Chemotherapy Volume 81, Issue 1抗菌化疗杂志81卷 1期 https://academic.oup.com/jac/issue 50th Anniversary Collection（50周年纪念合集） Review（综述） 1 Artificial intelligence for improving decision-making in bacterial infection management: a narrative review 人工智能在改善细菌感染治疗决策中的应用：一项叙述性综述 Anisia Talianu and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf470, https://doi.org/10.1093/jac/dkaf470 Reviews（综述） 2 Evolving landscape of methicillin-resistant Staphylococcus pseudintermedius: the emergence of new epidemic waves across Europe, Asia and North America 耐甲氧西林中间型葡萄球菌的演变格局：欧洲、亚洲和北美洲新流行浪潮的出现 Lillian Rose Giarratana and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf340, https://doi.org/10.1093/jac/dkaf340 3 Azithromycin resistance in non-typhoidal Salmonella: a review 非伤寒沙门氏菌对阿奇霉素的耐药性：综述 Zhe Zhu and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf341, https://doi.org/10.1093/jac/dkaf341 4 Antibiotic pharmacodynamics: from MIC to advanced metrics and their applications 抗生素药效动力学：从最低抑菌浓度到高级指标及其应用 Malin Andersson and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf374, https://doi.org/10.1093/jac/dkaf374 5 Progress in the study of drug resistance mechanism of Bacillus cereus 蜡样芽孢杆菌耐药机制研究进展 Yuhang Zhang and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf399, https://doi.org/10.1093/jac/dkaf399 6 The curious constraints on clofazimine 氯法齐明的奇特限制 Maple Goh and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf430, https://doi.org/10.1093/jac/dkaf430 7 Antiplasmid systems: a novel strategy to combat antibiotic resistance 抗质粒系统：对抗抗生素耐药性的新策略 Mohd Asim and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf472, https://doi.org/10.1093/jac/dkaf472 Systematic Review（系统综述） 8 Coccidioidomycosis in Europe: a systematic literature review of epidemiology, treatment and outcomes 欧洲球孢子菌病：流行病学、治疗和预后的系统文献综述 Priya Shastri and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf407, https://doi.org/10.1093/jac/dkaf407 9 Systematic review of antimicrobial pharmacokinetic/pharmacodynamic indices in murine thigh and hollow fibre dose fractionation studies analysed with a standard method 用标准方法分析小鼠大腿和空心纤维剂量分次研究中的抗菌药物药代动力学/药效动力学指数的系统综述 Najla Alabdulkarim and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf446, https://doi.org/10.1093/jac/dkaf446 Virtual Roundtable（虚拟圆桌会议） 10 Procalcitonin in the management of lower respiratory tract infection and sepsis 降钙素原在下呼吸道感染和败血症治疗中的应用 Ramy H Elshaboury and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf298, https://doi.org/10.1093/jac/dkaf298 Original Research（论著） 11 Model-based assessment of letermovir pharmacokinetics in allogeneic haematopoietic stem cell transplant recipients 来特莫韦在异基因造血干细胞移植受者中药代动力学的基于模型的评估 Chrisoula Tahtsidou and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf427, https://doi.org/10.1093/jac/dkaf427 12 In vitro exebacase (CF-301) activity against methicillin-susceptible or methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci strains isolated from patients with infective endocarditis 体外试验评估依拉环素（CF-301）对甲氧西林敏感或甲氧西林耐药金黄色葡萄球菌及凝固酶阴性葡萄球菌（从感染性心内膜炎患者中分离）的活性 María-Alexandra Cañas and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf435, https://doi.org/10.1093/jac/dkaf435 13 Evaluation of subcutaneous amoxicillin/clavulanic acid pharmacokinetics as an alternative to the intravenous route in older patients—the PhASAge Study 评估皮下注射阿莫西林/克拉维酸药代动力学作为老年患者静脉给药替代方案——PhASAge研究 Nicolas Grégoire and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf381, https://doi.org/10.1093/jac/dkaf381 14 Real-life use of isavuconazole in Spanish children and adolescents 西班牙儿童和青少年中艾沙康唑的实际使用情况 Natalia Mendoza-Palomar and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf394, https://doi.org/10.1093/jac/dkaf394 15 No pharmacovigilance signal of intracranial hypertension associated with glycylcyclines: a FAERS-based disproportionality analysis 基于FAERS数据库的不成比例性分析：未发现甘氨酰环素类与颅内高压相关的药物警戒信号 Slobodan M Jankovic and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf395, https://doi.org/10.1093/jac/dkaf395 16 Posaconazole enteral tube administration in adults: pharmacokinetic target attainment of oral suspension compared with crushed delayed-release tablet 成人经肠内营养管给予泊沙康唑：口服混悬液与碾碎的缓释片的药代动力学目标达成情况比较 Nirjan Bhattarai and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf396, https://doi.org/10.1093/jac/dkaf396 17 Characterizing CYP3A4-mediated drug interactions: a fixed-sequence pharmacokinetic Chinese study of posaconazole and ruxolitinib in haematological malignancies CYP3A4介导的药物相互作用特征：一项关于泊沙康唑和鲁索替尼在血液系统恶性肿瘤中的固定序列药代动力学中国研究 Beibei Liang and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf398, https://doi.org/10.1093/jac/dkaf398 18 Differences in prescription for impetigo and cellulitis across years in three European countries 三个欧洲国家不同年份脓疱病和蜂窝织炎的处方差异 Thomas Bettuzzi and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf400, https://doi.org/10.1093/jac/dkaf400 19 β-Lactam concentrations monitored in the early phase of community-acquired sepsis in the intensive care unit 重症监护室社区获得性脓毒症早期阶段监测的β-内酰胺浓度 Karolina Liljedahl Prytz and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf401, https://doi.org/10.1093/jac/dkaf401 20 Enhanced antimycobacterial efficacy of simulated inhaled clofazimine versus oral clofazimine in combination with azithromycin and ethambutol in a hollow-fiber system 在空心纤维系统中，模拟吸入氯法齐明与口服氯法齐明联合阿奇霉素和乙胺丁醇的抗结核分枝杆菌疗效增强比较 Jelmer Raaijmakers and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf402, https://doi.org/10.1093/jac/dkaf402 21 Identification of antimicrobial resistance genes in Escherichia coli through network diffusion 通过网络扩散法鉴定大肠杆菌中的抗生素耐药基因 Anis Mansouri and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf404, https://doi.org/10.1093/jac/dkaf404 22 Preclinical evaluation of epetraborole in the hollow fibre system model of Mycobacterium abscessus lung disease 依培硼罗在脓肿分枝杆菌肺病空心纤维系统模型中的临床前评估 Sanjay Singh and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf405, https://doi.org/10.1093/jac/dkaf405 23 The β-lactamase inhibitor concentration-dependent minimum inhibitory concentration (MICcBLI) as methodology to assess the pharmacokinetic/pharmacodynamic relationship of piperacillin/tazobactam for dosing optimization β-内酰胺酶抑制剂浓度依赖性最低抑菌浓度（MICcBLI）作为评估哌拉西林/他唑巴坦药代动力学/药效动力学关系以优化给药的方法 Malin Andersson and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf406, https://doi.org/10.1093/jac/dkaf406 24 Unravelling the triad of penicillin-binding proteins, β-lactamase activity, and mRNA dynamics in Pseudomonas aeruginosa AmpC induction 解析铜绿假单胞菌AmpC诱导过程中青霉素结合蛋白、β-内酰胺酶活性和mRNA动态的三元关系 Maria Montaner and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf408, https://doi.org/10.1093/jac/dkaf408 25 Unnoticed spread of linear VanA-plasmids in vancomycin-variable Enterococcus faecium strains across different regions: a diagnostics challenge 不同地区万古霉素可变型粪肠球菌菌株中线性VanA质粒的未被察觉的传播：一项诊断挑战 Ana C Almeida-Santos and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf409, https://doi.org/10.1093/jac/dkaf409 26 Switching from etravirine to doravirine in virologically suppressed people with HIV: results from the French multicentre SWEED observational study 在病毒学抑制的HIV感染者中从依曲韦林切换至多拉韦林：法国多中心SWEED观察性研究的结果 Romain Palich and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf410, https://doi.org/10.1093/jac/dkaf410 27 HIV-1 drug resistance among pregnant and breastfeeding mothers and its association with paediatric HIV infections in the Dolutegravir era in Uganda 乌干达多替拉韦时代孕产妇及哺乳期母亲中HIV-1耐药情况及其与儿童HIV感染的关联 Anne Kapaata and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf411, https://doi.org/10.1093/jac/dkaf411 28 Outpatient antibiotic prescribing for medically attended respiratory syncytial virus, influenza, or human metapneumovirus illness among high-risk adults in rural Wisconsin, United States 美国威斯康星州农村地区高风险成人因呼吸道合胞病毒、流感或人偏肺病毒感染就诊时的门诊抗生素处方情况 Sarah C J Jorgensen and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf412, https://doi.org/10.1093/jac/dkaf412 29 Omadacycline as a drug candidate for Mycobacterium avium infections: in vitro insights on single and combination therapies 奥马环素作为鸟分枝杆菌感染候选药物：单药及联合治疗的体外研究 Saskia E Mudde and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf413, https://doi.org/10.1093/jac/dkaf413 30 Post-pandemic trends in Streptococcus pneumoniae serotype epidemiology and antibiotic susceptibility in adults with invasive and non-invasive pneumococcal disease in the USA (2022–2023) 后疫情时代美国成人侵袭性与非侵袭性肺炎链球菌病血清型流行病学及抗生素敏感性趋势（2022-2023） Mekki F Bensaci and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf414, https://doi.org/10.1093/jac/dkaf414 31 Benznidazole pharmacokinetics in patients with chronic Chagas disease: association with demographic factors and adverse drug reactions 慢性恰加斯病患者苯芴醇药代动力学：与人口统计学因素及药物不良反应的关联 Gabriel P E Silveira and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf416, https://doi.org/10.1093/jac/dkaf416 32 Acquired antimicrobial resistance genes in Bordetella Species: a global genomic analysis 博德特氏菌属中获得的抗菌药物耐药基因：全球基因组分析 Biao Tang and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf418, https://doi.org/10.1093/jac/dkaf418 33 Machine learning for personalized antimicrobial susceptibility breakpoints: (Adaptive clinical breakpoint interpretation) 基于机器学习的个性化抗菌药物敏感性折点制定（自适应临床折点解释） Yinzheng Zhong and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf419, https://doi.org/10.1093/jac/dkaf419 34 Multicentre investigation of Wickerhamomyces anomalus fungemia in India: emerging resistance and mechanistic insights 印度异常威克汉姆酵母菌血症的多中心研究：新发耐药性及机制洞察 Shristi Verma and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf420, https://doi.org/10.1093/jac/dkaf420 35 Reducing aztreonam/avibactam waste: insights from Monte Carlo simulations 减少氨曲南/阿维巴坦浪费：蒙特卡洛模拟的启示 Yeleen Fromage and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf421, https://doi.org/10.1093/jac/dkaf421 36 Nanoparticle-based co-delivery of ciprofloxacin and meropenem enhances synergistic activity against multidrug-resistant hypervirulent Klebsiella pneumoniae clinical isolates 基于纳米颗粒的环丙沙星与美罗培南共递送可增强对多重耐药高毒力肺炎克雷伯菌临床分离株的协同活性 Reham Mostafa and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf422, https://doi.org/10.1093/jac/dkaf422 37 Development of population pharmacokinetic models of total and free piperacillin in critically ill children and young adults for Monte Carlo simulations and model-informed precision dosing 危重症儿童及青年总游离哌拉西林群体药代动力学模型开发：用于蒙特卡洛模拟及模型引导的精准给药 Sonya Tang Girdwood and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf423, https://doi.org/10.1093/jac/dkaf423 38 Reaching the target: time and dose required to achieve target vancomycin plasma concentrations in admitted patients 达标分析：住院患者达到目标万古霉素血浆浓度所需的时间与剂量 W Töpfer and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf424, https://doi.org/10.1093/jac/dkaf424 39 Notable transmitted HIV drug resistance among people who inject drugs in Pakistan 巴基斯坦注射毒品人群中显著传播的HIV耐药性 Stephanie Melnychuk and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf425, https://doi.org/10.1093/jac/dkaf425 40 Synergistic but clinically unattainable: amoxicillin/ceftriaxone combination against ampicillin-susceptible Enterococcus faecium 协同但临床难以实现：阿莫西林/头孢曲松联合对氨苄西林敏感粪肠球菌的体外活性 Ahmed Ashrin and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf426, https://doi.org/10.1093/jac/dkaf426 41 Pharmacodynamic studies of taniborbactam (VNRX-5133) combined with cefepime against β-lactamase–producing Gram-negative bacteria in a neutropenic murine thigh infection model 中性粒细胞减少小鼠大腿感染模型中他尼硼巴坦（VNRX-5133）联合头孢吡肟对产β-内酰胺酶革兰氏阴性菌的药效动力学研究 Panagiota-Christina Georgiou and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf431, https://doi.org/10.1093/jac/dkaf431 42 Epidemiology and treatment of endocarditis secondary to Enterobacterales other than Serratia spp. 非塞拉蒂亚属肠杆菌目细菌所致心内膜炎的流行病学及治疗 Clayton F Hausberger and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf432, https://doi.org/10.1093/jac/dkaf432 43 Enhanced activity of apramycin and apramycin-based combinations against Mycobacteroides abscessus 阿普拉霉素及其组合对脓肿分枝杆菌的增强活性 Yanqin Huang and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf433, https://doi.org/10.1093/jac/dkaf433 44 Efflux-mediated multidrug resistance mechanism in Trichophyton indotineae and Trichophyton rubrum; role of ABC transporters and MFS gene 印度毛癣菌与红色毛癣菌中由ABC转运蛋白和MFS基因介导的流出泵型多重耐药机制 Dipika Shaw and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf434, https://doi.org/10.1093/jac/dkaf434 45 Sphingobacterium spp. as intrinsic producers of SPI Ambler class B metallo-β-lactamases 鞘氨醇杆菌属作为SPI Ambler B类金属β-内酰胺酶的固有产生者 Delphine Girlich and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf436, https://doi.org/10.1093/jac/dkaf436 46 Global phylogeography and genomic characterization of blaNDM-1-positive carbapenem-resistant Acinetobacter soli blaNDM-1阳性碳青霉烯耐药溶胶阿卡净菌的全球系统发育地理学及基因组特征 Pengpeng Min and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf437, https://doi.org/10.1093/jac/dkaf437 47 Pharmacokinetics and tolerability of one-month daily rifapentine for latent tuberculosis treatment in haemodialysis patients 血液透析患者潜伏性结核治疗中每月一次每日利福喷丁的药代动力学及耐受性 Thornthun Ueaphongsukkit and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf439, https://doi.org/10.1093/jac/dkaf439 48 In vitro susceptibility of cefepime-enmetazobactam, cefepime-taniborbactam and cefepime-zidebactam towards carbapenemase-producing Enterobacterales 头孢吡肟-恩美他唑巴坦、头孢吡肟-他尼硼巴坦及头孢吡肟-齐德巴坦对产碳青霉烯酶肠杆菌目的体外敏感性 Marion Dutkiewicz and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf440, https://doi.org/10.1093/jac/dkaf440 49 In vitro efficacy of sulbactam/durlobactam combined with β-lactam antibiotics in Australian Mycobacterium abscessus isolates 舒巴坦/杜洛巴坦联合β-内酰胺类抗生素对澳大利亚脓肿分枝杆菌分离株的体外疗效 Kirby Patterson-Fahy and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf441, https://doi.org/10.1093/jac/dkaf441 50 Harnessing CRISPR–Cas9 and CRISPRi systems to reverse antibiotic resistance in a clinical multidrug-resistant Escherichia coli isolate 利用CRISPR-Cas9及CRISPRi系统逆转临床多重耐药大肠杆菌分离株的抗生素耐药性 Ruonan Zhao and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf442, https://doi.org/10.1093/jac/dkaf442 51 Cotrimoxazole in the intensive care unit: an impossible task for the fixed association in real life? 重症监护室中复方磺胺甲噁唑的应用：固定组合在现实中的不可行性？ Manon Launay and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf443, https://doi.org/10.1093/jac/dkaf443 52 National representative survey of pretreatment HIV drug resistance in Colombia: analysis of antiretroviral resistance-associated mutations using next-generation sequencing 哥伦比亚全国代表性调查：基于下一代测序的抗逆转录病毒耐药相关突变分析 Ernesto Martínez-Buitrago and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf444, https://doi.org/10.1093/jac/dkaf444 53 A model-based comparison of dose reduction strategies for fixed-dose dolutegravir-containing regimens 基于模型的含固定剂量多替拉韦方案减量策略比较 Laura Dickinson and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf445, https://doi.org/10.1093/jac/dkaf445 54 Therapeutic drug monitoring and target attainment of unbound flucloxacillin in hospitalized patients with measured MICs (FLUTE) 住院患者中游离氟氯西林的治疗药物监测及目标达成情况（基于实测最低抑菌浓度的FLUTE研究） Pjotr P Temme and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf447, https://doi.org/10.1093/jac/dkaf447 55 Nirmatrelvir-ritonavir addition to acute care formulary: a retrospective, multi-centre evaluation of quantitative economic and qualitative clinical outcomes 奈玛特韦/利托那韦纳入急症治疗目录：一项多中心回顾性评估定量经济与定性临床结果的研究 Jose Valdes Ledesma and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf448, https://doi.org/10.1093/jac/dkaf448 56 Local antibiotic resistance surveillance in nursing homes using lot quality assurance sampling: a feasibility study 采用批量质量保证抽样法对养老院进行本地抗生素耐药性监测的可行性研究 Sacha Kuil and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf451, https://doi.org/10.1093/jac/dkaf451 57 High in vitro activity of the novel antimicrobial gepotidacin against Neisseria gonorrhoeae isolates in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021–24 2021-2024年，在世卫组织三个区域的八个世卫组织增强淋球菌抗菌药物监测计划国家中，新型抗菌药物吉皮达星对淋病奈瑟菌分离株的体外活性较高 Josefine Ahlstrand and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf452, https://doi.org/10.1093/jac/dkaf452 58 Despite increasing use of integrase inhibitors to treat HIV infection, resistance to this class remains stable 尽管整合酶抑制剂用于治疗HIV感染的使用量不断增加，但此类药物的耐药性仍保持稳定 Cathia Soulie and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf454, https://doi.org/10.1093/jac/dkaf454 59 Fine-needle aspiration in infected necrotizing pancreatitis in the delayed intervention era: a post hoc analysis of safety, microbiological yield and therapeutic implications 延迟干预时代感染性坏死性胰腺炎的细针穿刺抽吸术：安全性、微生物学检出率及治疗意义的事后分析 Hannah S Pauw and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf455, https://doi.org/10.1093/jac/dkaf455 60 β-Lactam dosing in critically ill children: predictors for target non-attainment 危重症儿童β-内酰胺类药物给药：未达目标浓度的预测因素 Stef Schouwenburg and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf457, https://doi.org/10.1093/jac/dkaf457 61 Co-administration of triazoles with calcineurin or mammalian target of rapamycin inhibitors in solid organ transplant patients hospitalized with invasive aspergillosis 实体器官移植患者合并侵袭性曲霉病住院时三唑类药物与钙调磷酸酶抑制剂或哺乳动物雷帕霉素靶蛋白抑制剂的联合用药情况 Barbara Alexander and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf461, https://doi.org/10.1093/jac/dkaf461 62 In vitro selection of cefiderocol-resistant mutants in Acinetobacter baumannii harbouring the most common carbapenemase genes 携带最常见碳青霉烯酶基因的鲍曼不动杆菌中头孢地尔耐药突变体的体外筛选 Otávio Hallal Ferreira Raro and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf462, https://doi.org/10.1093/jac/dkaf462 63 Preventing resistance development in infections by OXA β-lactamase-producing Pseudomonas aeruginosa: correlating clinical outcomes with hollow-fibre model input 预防产OXA β-内酰胺酶铜绿假单胞菌感染耐药性的产生：将临床结局与中空纤维模型输入相关联 María M Montero and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf464, https://doi.org/10.1093/jac/dkaf464 64 A national pilot community pharmacy–led urinary tract infection service: clinical and patient-reported outcomes from 9077 consultations 全国社区药房主导的尿路感染服务试点项目：9077次咨询的临床结局和患者报告结局 Efi Mantzourani and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf466, https://doi.org/10.1093/jac/dkaf466 65 Towards enhanced translational value: preclinical drug activity testing against actively multiplying, nutrient-starved and pellicle biofilm-embedded Mycobacterium abscessus 提高转化价值：针对活跃增殖、营养匮乏和生物膜包裹的脓肿分枝杆菌进行临床前药物活性测试 Henriëtte M Meliefste and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf468, https://doi.org/10.1093/jac/dkaf468 Research Letters（研究快报） 66 Novel multiresistance transposon Tn7731 in bovine Pasteurella multocida from Germany 德国牛源多杀性巴氏杆菌中新型多重耐药转座子Tn7731 Henrike Krüger-Haker and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf336, https://doi.org/10.1093/jac/dkaf336 67 Efficacy of eravacycline in difficult-to-treat (DTR) Acinetobacter baumannii bacteraemia in ICU: a case report 厄他培南治疗重症监护病房难治性鲍曼不动杆菌菌血症的疗效：一例病例报告 Monica Melchio and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf347, https://doi.org/10.1093/jac/dkaf347 68 Possible increased risk of Epstein–Barr virus (EBV) infection and post-transplant lymphoproliferative disease (PTLD) in letermovir-exposed haematopoietic cell transplantation recipients 来特莫韦暴露的造血细胞移植受者中EB病毒感染和移植后淋巴增殖性疾病风险可能增加 Jose F Camargo and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf348, https://doi.org/10.1093/jac/dkaf348 69 Dalbavancin dosing in a severely underweight woman with prosthetic valve endocarditis: the critical role of proactive therapeutic drug monitoring 达巴万星在严重体重不足人工瓣膜心内膜炎女性患者中的给药：主动治疗药物监测的关键作用 Ambra Barco and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf365, https://doi.org/10.1093/jac/dkaf365 70 Cefazolin-induced seizures in a haemodialysis patient with elevated serum and cerebrospinal fluid concentrations: a case report 血液透析患者头孢唑林血清和脑脊液浓度升高诱发癫痫：一例病例报告 Kohei Hasegawa and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf373, https://doi.org/10.1093/jac/dkaf373 71 Retrospective analysis of pharmacological therapeutic monitoring of caspofungin in patients undergoing continuous renal replacement therapy using polyacrylonitrile membranes 使用聚丙烯腈膜进行连续性肾脏替代治疗的患者中卡泊芬净药代动力学治疗监测的回顾性分析 Antoine Hérault and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf390, https://doi.org/10.1093/jac/dkaf390 72 Diffusion of OXA-48- and NDM-5-producing Klebsiella pneumoniae ST383 clone in Central Italy 产OXA-48和NDM-5的肺炎克雷伯菌ST383克隆在意大利中部的传播 Gloria D’Achille and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf397, https://doi.org/10.1093/jac/dkaf397 73 Durability of lenacapavir in viremic heavily treatment-experienced people with HIV: real-world data from the PRESTIGIO Registry 来那卡帕韦在病毒载量阳性且接受过大量抗逆转录病毒治疗的HIV感染者中的持久性：来自PRESTIGIO登记处的现实数据 Tommaso Clemente and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf415, https://doi.org/10.1093/jac/dkaf415 74 Co-carriage of the oxazolidinone resistance genes cfr and optrA in a linezolid-resistant Staphylococcus rostri isolate from a pig-farm worker 猪场工人利奈唑胺耐药猪鼻支原体分离株中噁唑烷酮类耐药基因cfr和optrA的共携带情况 Gi Yong Lee and Soo-Jin Yang Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf428, https://doi.org/10.1093/jac/dkaf428 75 Importance of reviewing the package insert from gradient strip manufacturers 梯度扩散法药敏纸片生产商说明书审阅的重要性 Mandy Wootton and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf429, https://doi.org/10.1093/jac/dkaf429 76 One resistance gene, many transposons: repeated formation of compound and pseudo-compound transposons carrying the aphA1 kanamycin and neomycin resistance gene 一个耐药基因，多个转座子：携带aphA1卡那霉素和新霉素耐药基因的复合及假复合转座子的重复形成 Christopher J Harmer and Ruth M Hall Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf450, https://doi.org/10.1093/jac/dkaf450 77 Absence of lymphogranuloma venereum among men who have sex with men on PrEP receiving doxycycline postexposure prophylaxis 接受暴露后多西环素预防性治疗的暴露前预防用药男男性行为者中未发现性病淋巴肉芽肿 Cristina Gómez-Ayerbe and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf456, https://doi.org/10.1093/jac/dkaf456 78 In vitro activity of gepotidacin against Chlamydia trachomatis 吉皮达星对沙眼衣原体的体外活性 Arabella Touati and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf460, https://doi.org/10.1093/jac/dkaf460 Journal of Antimicrobial Chemotherapy Volume 81, Issue 2抗菌化疗杂志 81卷 2期 https://academic.oup.com/jac/issue Viewpoints（观点） 1 Long-acting glycopeptides: what are the barriers to access in patients who need them most, and how can they be overcome? 长效糖肽类：最需要它们的患者获取药物的障碍有哪些，如何克服？ Aleece MacPhail and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf471, https://doi.org/10.1093/jac/dkaf471 2 Redefining antifungal prophylaxis in acute leukaemia in the era of targeted therapies 靶向治疗时代急性白血病抗真菌预防的重新定义 Marcio Nucci and Johan Maertens Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag010, https://doi.org/10.1093/jac/dkag010 Reviews（综述） 3 Research progress on resistance mechanisms and clinical efficacy of tigecycline against Klebsiella pneumoniae 替加环素对肺炎克雷伯菌的耐药机制及临床疗效研究进展 Meilin Wu and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf504, https://doi.org/10.1093/jac/dkaf504 4 Liposomal amphotericin B and renal safety: review of the evidence and clinical considerations 两性霉素B脂质体与肾脏安全性：证据回顾及临床考量 Johan Maertens and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf473, https://doi.org/10.1093/jac/dkaf473 5 Strategies for mitigating severe COVID-19 in patients with haematological malignancy during the omicron era 奥密克戎时代减轻血液系统恶性肿瘤患者严重新冠肺炎的策略 Keiji Okinaka and Joshua T Schiffer Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf489, https://doi.org/10.1093/jac/dkaf489 Systematic Reviews（系统综述） 6 Safety and efficacy of gepotidacin in urinary tract infection: a GRADE-assessed systematic review and meta-analysis 吉泊替达辛治疗尿路感染的安全性和有效性：一项基于GRADE评估的系统综述和荟萃分析 Taha Ibrahim and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf469, https://doi.org/10.1093/jac/dkaf469 7 The emerging clinical relevance and antimicrobial resistance of Pluralibacter gergoviae: a systematic review 产吲哚金黄杆菌日益凸显的临床相关性和抗菌药物耐药性：一项系统综述 Bruna Abdul Ahad Saad and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf476, https://doi.org/10.1093/jac/dkaf476 8 A comprehensive analysis of the mutational landscape determining polymyxin resistance in Klebsiella pneumoniae 决定肺炎克雷伯菌多粘菌素耐药性的突变谱综合分析 Sambit Kumar Dwibedy and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf503, https://doi.org/10.1093/jac/dkaf503 9 Factors promoting or hindering self-administered outpatient parenteral antimicrobial therapy: a systematic literature review 促进或阻碍自我给药门诊静脉注射抗菌药物治疗的因素：一项系统文献综述 Hester H Stoorvogel and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf490, https://doi.org/10.1093/jac/dkaf490 Original Research（论著） 10 Cefepime/enmetazobactam for Gram-negative periprosthetic joint infections? A randomized porcine study on target tissue pharmacokinetics 头孢吡肟/恩美唑巴坦治疗革兰氏阴性假体周围关节感染？一项关于猪的靶组织药代动力学的随机研究 M B D Nielsen and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf487, https://doi.org/10.1093/jac/dkaf487 11 Impact of extracorporeal membrane oxygenation modes on voriconazole exposure in critically ill patients 体外膜肺氧合模式对危重患者伏立康唑暴露的影响 Xinrui Wang and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf501, https://doi.org/10.1093/jac/dkaf501 12 Model-based assessment of VRC07-523LS dosing in infants through population pharmacokinetic -pharmacodynamic modelling in adults and infants 基于模型通过成人和婴儿群体药代动力学-药效学模型评估VRC07-523LS在婴儿中的给药方案 Dustin Huynh and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf449, https://doi.org/10.1093/jac/dkaf449 13 Antibiotic resistance of Pseudomonas aeruginosa strains—intracellular metabolomics analysis 铜绿假单胞菌菌株的抗生素耐药性——细胞内代谢组学分析 Karolina Anna Mielko-Niziałek and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf453, https://doi.org/10.1093/jac/dkaf453 14 In vitro activity of cefepime/zidebactam against sulbactam/durlobactam-susceptible and -resistant Acinetobacter baumannii clinical isolates 头孢吡肟/齐多巴坦对舒巴坦/杜洛巴坦敏感和耐药鲍曼不动杆菌临床分离株的体外活性 Carlo Tascini and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf467, https://doi.org/10.1093/jac/dkaf467 15 Prevalence of macrolide resistance in Mycoplasma pneumoniae in The Netherlands 荷兰肺炎支原体大环内酯类抗生素耐药性的流行情况 Patrick D J Sturm and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf475, https://doi.org/10.1093/jac/dkaf475 16 Simulated lung exposure in pneumonia patients to evaluate the antibacterial capacity and resistance suppression of clinical tigecycline regimens against carbapenem-resistant Acinetobacter baumannii 模拟肺炎患者肺部暴露情况以评估临床替加环素方案对碳青霉烯类耐药鲍曼不动杆菌的抗菌能力和耐药抑制作用 Xiaonan Zhang and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf477, https://doi.org/10.1093/jac/dkaf477 17 Enterococcus faecium harbouring vanA, optrA and cfr(D) on a linear plasmid in Canada: a CANWARD surveillance case 加拿大发现携带vanA、optrA和cfr(D)的粪肠球菌线性质粒：一项CANWARD监测病例 Melissa McCracken and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf478, https://doi.org/10.1093/jac/dkaf478 18 The effect of intrauterine exposure to aminoglycosides on neonatal hearing 宫内暴露于氨基糖苷类抗生素对新生儿听力的影响 Daniel Leshin-Carmel and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf483, https://doi.org/10.1093/jac/dkaf483 19 Ceftazidime/avibactam: a potent arsenal against multidrug-resistant Pseudomonas aeruginosa-unveiling in vitro and in vivo strategies 头孢他啶/阿维巴坦：对抗多重耐药铜绿假单胞菌的有力武器——揭示体内外策略 Jiaju Zhuo and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf495, https://doi.org/10.1093/jac/dkaf495 20 Comparison of disk diffusion, MIC test strip and broth microdilution for eravacycline susceptibility testing of 422 Staphylococcus aureus isolates using ChinaCAST breakpoints 采用中国CAST折点，比较422株金黄色葡萄球菌对依拉环素的纸片扩散法、最低抑菌浓度测试条法和肉汤微量稀释法的敏感性测试结果 Xinying Wang and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf502, https://doi.org/10.1093/jac/dkaf502 21 Penetration of daptomycin in cerebrospinal fluid during pneumococcal meningitis 肺炎链球菌性脑膜炎期间达托霉素在脑脊液中的渗透情况 Pascal Chavanet and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf474, https://doi.org/10.1093/jac/dkaf474 22 Rapid molecular diagnostics for detection of extensively drug-resistant Salmonella Typhi 用于检测广泛耐药伤寒沙门菌的快速分子诊断技术 Emma L Sweeney and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf481, https://doi.org/10.1093/jac/dkaf481 23 Gender inequality and antibiotic consumption: analysis of pharmaceutical sales data from 70 countries, 2000–22 性别不平等与抗生素消费：基于2000 - 2022年70个国家药品销售数据的分析 Deepshikha Batheja and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag002, https://doi.org/10.1093/jac/dkag002 24 Real-world evaluation of isavuconazole in children with cancer 伊沙康唑在儿童癌症患者中的现实应用评估 Janine Nijhuis and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf485, https://doi.org/10.1093/jac/dkaf485 25 Assessing antimicrobial susceptibility testing guideline adherence by laboratories providing bacteriology services in Ghana: a pilot study 加纳提供细菌学服务的实验室对抗菌药物敏感性试验指南依从性的评估：一项试点研究 Joseph Elikem Efui Acolatse and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag003, https://doi.org/10.1093/jac/dkag003 26 Resistance to second-generation integrase inhibitors in people with HIV following treatment failure on dolutegravir- or bictegravir-based ART in Taiwan 台湾地区基于多替拉韦或比克替拉韦的抗逆转录病毒治疗失败后，HIV感染者对第二代整合酶抑制剂的耐药性 Guan-Jhou Chen and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf488, https://doi.org/10.1093/jac/dkaf488 27 In vitro activity of gepotidacin against a challenging panel of multidrug-resistant Neisseria gonorrhoeae isolates 吉泊西汀对一组具有挑战性的多重耐药淋病奈瑟菌分离株的体外活性 Michelle Jayne Cole and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag001, https://doi.org/10.1093/jac/dkag001 28 A disproportionality analysis of adverse events associated with omadacycline based on the FDA adverse event reporting system database 基于美国食品药品监督管理局（FDA）不良事件报告系统数据库的奥马环素相关不良事件比例失衡分析 Ye-Lei Zhao and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag006, https://doi.org/10.1093/jac/dkag006 29 Weight-band-based simplification of oral allometric miltefosine dosing in paediatric patients with visceral leishmaniasis 基于体重范围的口服异速缩放米替福新给药方案在儿童内脏利什曼病患者中的简化应用 Andres Mazariegos Herrera and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag014, https://doi.org/10.1093/jac/dkag014 30 evelopment of a capability framework for antimicrobial stewardship specialist health professionals working in the NHS in England: utilizing Delphi methodology 运用德尔菲法为在英国国家医疗服务体系（NHS）中工作的抗菌药物管理专业人员制定能力框架 Ryan A Hamilton and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf438, https://doi.org/10.1093/jac/dkaf438 31 First characterization of insertions in the HIV-1 integrase-coding region from people with HIV 首次对来自艾滋病病毒感染者的HIV-1整合酶编码区插入情况进行特征分析 Nhat Quang Tu and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf491, https://doi.org/10.1093/jac/dkaf491 32 Development of an impedance-based fast antimicrobial susceptibility test for Neisseria gonorrhoeae 开发一种基于阻抗的淋病奈瑟菌快速抗菌药物敏感性检测方法 Caitlin N Daniels and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf493, https://doi.org/10.1093/jac/dkaf493 33 Juvenile toxicity and developmental safety of Zintrodiazine, a novel antimalarial candidate, in Wistar rats 新型抗疟候选药物Zintrodiazine在Wistar大鼠中的幼年毒性和发育安全性研究 Hitesh A Kadu and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag008, https://doi.org/10.1093/jac/dkag008 34 Do the redefined EUCAST susceptibility categories warrant adjustment of paediatric antibiotic dosages? Pragmatic physiologically based pharmacokinetic modelling of four commonly used agents 欧洲抗微生物药物敏感性试验委员会（EUCAST）重新定义的敏感性分类是否需要调整儿童抗生素剂量？——对四种常用药物的实用生理药代动力学建模研究 Marika A de Hoop-Sommen and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf463, https://doi.org/10.1093/jac/dkaf463 35 Exploring the opportunity for therapeutic drug monitoring (TDM) and precision dose antimicrobials in an outpatient antimicrobial therapy (OPAT) service: a prospective observational study 门诊抗菌治疗（OPAT）服务中开展治疗药物监测（TDM）和精准剂量抗菌治疗的机遇：一项前瞻性观察研究 R C Wilson and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf484, https://doi.org/10.1093/jac/dkaf484 36 Impact of sex, age and body composition on rilpivirine and cabotegravir trough concentrations in people with HIV receiving long-acting injectable antiretroviral therapy 性别、年龄和身体成分对接受长效注射用抗逆转录病毒治疗的HIV感染者利匹韦林和卡博特韦谷浓度的影响 Maria Vittoria Cossu and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag024, https://doi.org/10.1093/jac/dkag024 37 Pharmacokinetics of cefiderocol during prolonged intermittent kidney replacement therapy in two patients with septic shock 头孢地尔在两例感染性休克患者长时间间歇性肾脏替代治疗期间的药代动力学 Julius J Schmidt and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf496, https://doi.org/10.1093/jac/dkaf496 38 Understanding mechanisms of reduced cefiderocol susceptibility in pvdS and fecI mutants of Pseudomonas aeruginosa 了解铜绿假单胞菌pvdS和fecI突变体对头孢地尔敏感性降低的机制 Yoshinori Yamano and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag004, https://doi.org/10.1093/jac/dkag004 39 Biomarker-informed PBPK modelling of meropenem in paediatric severe pneumonia: implications for target-site PK/PD 基于生物标志物的美罗培南在儿童重症肺炎中的生理药动学模型构建：对靶部位药代动力学/药效学的影响 Yao Liu and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf500, https://doi.org/10.1093/jac/dkaf500 40 Evaluating hypoalbuminaemia thresholds associated with delayed blood sterilization among patients receiving cefazolin or antistaphylococcal penicillins for MSSA bacteraemia 评估接受头孢唑林或抗葡萄球菌青霉素治疗甲氧西林敏感金黄色葡萄球菌（MSSA）菌血症患者中，与血液延迟灭菌相关的低白蛋白血症阈值 Sunish Shah and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf498, https://doi.org/10.1093/jac/dkaf498 Research Letters（研究快讯） 41 False-negative result in fourth-generation HIV screening tests after weak detection of p24 antigen in the context of inappropriate post-exposure prophylaxis use: a case report 不当使用暴露后预防用药导致第四代HIV筛查试验p24抗原弱检出后出现假阴性结果：一例病例报告 J Kimmerlin and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf459, https://doi.org/10.1093/jac/dkaf459 42 Proposal for the nomenclature of tmexCD-toprJ-like gene clusters 关于tmexCD-toprJ样基因簇命名的建议 Chengzhen Wang and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf482, https://doi.org/10.1093/jac/dkaf482 43 IS26-mediated chromosomal integration of virulence plasmid fragments in ST2237 carbapenem-resistant Klebsiella pneumoniae IS26介导的毒力质粒片段在ST2237型碳青霉烯耐药肺炎克雷伯菌染色体中的整合 Yan Li and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag018, https://doi.org/10.1093/jac/dkag018 Letter to the Editor（致编辑的信） 44 Comment on: Retrospective analysis of pharmacological therapeutic monitoring of caspofungin in patients undergoing continuous renal replacement therapy using polyacrylonitrile membranes 对“采用聚丙烯腈膜对接受连续性肾脏替代治疗的患者进行卡泊芬净药代动力学监测的回顾性分析”的评论 Gwénola Marais and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf465, https://doi.org/10.1093/jac/dkaf465 45 Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy-right-to-reply 意大利米兰地区使用多西环素暴露后预防（DoxyPEP）人群中，用于治疗细菌性传播感染的抗菌药物使用情况——回应说明 Angelo Roberto Raccagni and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag027, https://doi.org/10.1093/jac/dkag027 ACKNOWLEDGEMENT OF REFEREES（鸣谢审稿专家） 46 Acknowledgement of Referees 鸣谢审稿专家 Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf417, https://doi.org/10.1093/jac/dkaf417 CORRECTION（更正） 47 Correction to: Comment on: Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-Omicron or Omicron variants: a modelling analysis of the randomized DisCoVeRy trial 更正：关于Evusheld在感染奥密克戎变异株前或奥密克戎变异株的新冠住院患者中的抗病毒效果：对随机DisCoVeRy试验的建模分析的评论 Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf492, https://doi.org/10.1093/jac/dkaf492 Journal of Antimicrobial Chemotherapy Volume 81, Issue 3抗菌化疗杂志 81卷 3期 https://academic.oup.com/jac/issue REVIEW（综述） 1 Closing the PrEP access gap in Europe: a strategic framework for equity and innovation among difficult-to-reach populations 缩小欧洲暴露前预防获取差距：面向难以触及（PrEP）人群的公平与创新战略框架 Josep M Llibre and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag052, https://doi.org/10.1093/jac/dkag052 2 Precision dosing of systemic antifungals in adults: therapeutic drug monitoring, empiric dose optimization and barriers to implementation 成人全身性抗真菌药物的精准给药：治疗药物监测、经验性剂量优化及实施障碍 Daniel B Chastain and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag055, https://doi.org/10.1093/jac/dkag055 3 Bacterial DNA topoisomerase IV and DNA gyrase inhibitors: history of the quinolones, their clinical usage and potential alternatives for the future 细菌DNA拓扑异构酶IV和DNA旋转酶抑制剂：喹诺酮类药物的历史、临床应用及未来潜在替代方案 Daisuke Fukuda and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag054, https://doi.org/10.1093/jac/dkag054 4 Combating multidrug-resistant Klebsiella pneumoniae: current therapeutic regimens and future directions 应对多重耐药肺炎克雷伯菌：当前治疗方案与未来方向 Robiul Islam and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag064, https://doi.org/10.1093/jac/dkag064 SYSTEMATIC REVIEW（系统综述） 5 Global and regional prevalence of metallo-β-lactamases in carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis 耐碳青霉烯类鲍曼不动杆菌中金属β-内酰胺酶的全球和区域流行情况：一项系统综述和荟萃分析 Stamatis Karakonstantis and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag037, https://doi.org/10.1093/jac/dkag037 Original Research（论著） 6 The effect of oral ciprofloxacin at conventional doses on the QT interval in a tertiary outpatient setting 三级门诊常规剂量口服环丙沙星对患者QT间期的影响 Weber Liu and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag020, https://doi.org/10.1093/jac/dkag020 7 Bictegravir concentrations in breastmilk of healthy, lactating women without HIV 未感染人类免疫缺陷病毒（HIV）的健康哺乳期女性乳汁中的比克替拉韦浓度 L C van der Wekken-Pas and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag022, https://doi.org/10.1093/jac/dkag022 8 Management and outcomes of Stenotrophomonas maltophilia recovered from deep-site clinical specimens: a bicentric retrospective cohort study 从深部部位临床标本中分离出的嗜麦芽窄食单胞菌的治疗及转归：一项双中心回顾性队列研究 Anastasia Saade and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag021, https://doi.org/10.1093/jac/dkag021 9 Development of a risk prediction model for vancomycin-associated acute kidney injury: a multicentre retrospective study 万古霉素相关急性肾损伤风险预测模型的建立：一项多中心回顾性研究 Tomoyuki Ishigo and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag012, https://doi.org/10.1093/jac/dkag012 10 Cooperation between HIV-1 integrase natural polymorphism K156N and 3′PPT mutations in dolutegravir monotherapy failure HIV-1 整合酶天然多态性 K156N 与 3′PPT 突变在多替拉韦单药治疗失败中的协同作用 Jolieke A T van Osch and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag033, https://doi.org/10.1093/jac/dkag033 11 Impact of body mass index and serum albumin levels on isavuconazole plasma concentrations in patients with haematological malignancies 体重指数和血清白蛋白水平对血液系统恶性肿瘤患者艾沙康唑血浆浓度的影响 Jie Gao and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag032, https://doi.org/10.1093/jac/dkag032 12 Pharmacokinetics of cefotaxime and its metabolite desacetyl-cefotaxime to optimize dosing in critically ill children and children with sickle cell disease 用以优化危重症儿童和镰状细胞病儿童给药剂量的头孢噻肟及其代谢产物去乙酰头孢噻肟的药代动力学研究 Seef Abdalla and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag019, https://doi.org/10.1093/jac/dkag019 13 Summary of ceftriaxone-resistant Neisseria gonorrhoeae in Canada, 2017–24 2017 - 2024年加拿大头孢曲松耐药淋病奈瑟菌情况汇总 Robyn Thorington and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag007, https://doi.org/10.1093/jac/dkag007 14 Improving perioperative prophylactic antibiotic prescribing using a novel decision-support tool 使用新型决策支持工具改进围手术期预防性抗生素处方 Mark Mcintyre and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag015, https://doi.org/10.1093/jac/dkag015 15 Comparative activity of established versus new-generation β-lactams against AmpC-hyperproducing clinical isolates of Enterobacter cloacae complex and Klebsiella aerogenes: a multicentre study 针对产超广谱AmpC酶的阴沟肠杆菌复合群和产气克雷伯菌临床分离株，比较已上市与新一代β-内酰胺类抗生素的抗菌活性：一项多中心研究 Ángel Rodríguez-Villodres and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag034, https://doi.org/10.1093/jac/dkag034 16 Impact of eravacycline on fibrinogen 依拉环素对纤维蛋白原的影响 Emily Stevenson and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag030, https://doi.org/10.1093/jac/dkag030 17 Biliary pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime–avibactam in a case series of orthotopic liver transplant recipients 原位肝移植受者连续输注头孢他啶-阿维巴坦的药代动力学/药效学胆系分析：一项病例系列研究 Milo Gatti and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag009, https://doi.org/10.1093/jac/dkag009 18 Autoaggregation-associated carbapenem tolerance mediated by mrkH inactivation identified from a cohort of Klebsiella pneumoniae species complex clinical isolates 从肺炎克雷伯菌复合群临床分离株队列中鉴定出由mrkH失活介导的与自动聚集相关的碳青霉烯耐受性 Natsuki Yamanaka and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag017, https://doi.org/10.1093/jac/dkag017 19 In vitro activity of double and triple antimicrobial combinations against carbapenem-resistant Pseudomonas aeruginosa biofilm 双联和三联抗菌药物组合对碳青霉烯耐药铜绿假单胞菌生物膜的体外活性研究 Si-Ho Kim and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag031, https://doi.org/10.1093/jac/dkag031 20 LYSC98 as a novel vancomycin-derived agent effective against antibiotic-resistant pathogens in tolerant state LYSC98作为一种新型万古霉素衍生物，对耐受状态下的耐药病原体有效 Xing Xia and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag036, https://doi.org/10.1093/jac/dkag036 21 HBV status modulates transaminase decrease after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people with HIV HIV感染者从富马酸替诺福韦二吡呋酯切换为丙酚替诺福韦后，HBV状态对转氨酶下降的调节作用 Giuseppe Lapadula and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag045, https://doi.org/10.1093/jac/dkag045 22 Pharmacokinetics of colistin in adult critically ill patients in South Africa 南非成人危重症患者中多黏菌素的药代动力学研究 Veshni Pillay-Fuentes Lorente and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag011, https://doi.org/10.1093/jac/dkag011 23 Antifungal susceptibility surveillance of clinical moulds to olorofim, manogepix, amphotericin B, triazoles and echinocandins at 10 tertiary hospitals in China (2019–24) 2019 - 2024年中国10家三级医院临床霉菌对奥罗芬净、马诺盖匹克斯、两性霉素B、三唑类和棘白菌素类抗真菌药的敏感性监测 Su Chen and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag016, https://doi.org/10.1093/jac/dkag016 24 Short-cycle three-day-per-week efavirenz/emtricitabine/tenofovir disoproxil fumarate therapy: a seven-year extension study 短周期每周三日依非韦伦/恩曲他滨/富马酸替诺福韦二吡呋酯疗法：一项为期七年的延长研究 Beatriz Borjabad and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag040, https://doi.org/10.1093/jac/dkag040 25 Risk of hypertension in people with HIV in the USA initiating modern antiretroviral regimens: pooled analysis of blood pressure data from five clinical trials 美国感染HIV者启动现代抗逆转录病毒治疗方案后患高血压的风险：五项临床试验血压数据汇总分析 Priscilla Y Hsue and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag005, https://doi.org/10.1093/jac/dkag005 26 Real-world drug monitoring of dalbavancin using a three-dose regimen of 1500mg at days 1, 15 and 43 in bone and joint or cardiovascular infection 采用第1、15和43天各1500毫克的三剂量方案对达巴万星（Dalbavancin）在骨关节或心血管感染治疗中的实际药物监测研究 Thomas Lin and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag039, https://doi.org/10.1093/jac/dkag039 27 Nationwide patterns of HIV drug resistance and high viral load in Sub-Saharan African countries 撒哈拉以南非洲国家全国范围内的HIV耐药及高病毒载量模式 Abubaker Ibrahim Elbur and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkaf497, https://doi.org/10.1093/jac/dkaf497 28 Risk factors for suboptimal target attainment of commonly used ß-lactam antibiotics in older adults: a prospective cohort study 老年人常用β-内酰胺类抗生素未达最佳治疗目标的风险因素：一项前瞻性队列研究 Arnaud De Clercq and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag048, https://doi.org/10.1093/jac/dkag048 29 Physiologically based pharmacokinetic modelling to optimize dosing regimen of biapenem in renal impairment and elderly populations 基于生理的药代动力学模型优化肾功能不全及老年人群比阿培南给药方案 Wenyan Li and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkaf499, https://doi.org/10.1093/jac/dkaf499 30 Early targeted therapy guided by rapid phenotypic antimicrobial susceptibility testing in critically ill patients with Gram-negative bacterial bloodstream infections: a retrospective cohort study 快速表型抗菌药物敏感性试验指导下的早期目标性治疗对革兰氏阴性菌血流感染危重患者的效果：一项回顾性队列研究 Salvatore Rotundo and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag056, https://doi.org/10.1093/jac/dkag056 31 Impact of COVID-19-related healthcare changes on antibiotic resistance in clinical Escherichia coli isolates: interrupted time series analyses in Scotland, UK 与新冠肺炎相关的医疗变化对英国苏格兰地区临床大肠杆菌分离株抗生素耐药性的影响：中断时间序列分析 Laura Ciaccio and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag049, https://doi.org/10.1093/jac/dkag049 32 Multicentre evaluation of teicoplanin prescribing and monitoring in the UK and Ireland: the TUcK–SHOP study 英国和爱尔兰替考拉宁处方与监测的多中心评估：TUcK–SHOP研究 Stephen Hughes and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag038, https://doi.org/10.1093/jac/dkag038 33 Diabetes and risk of significant fibrosis in adults with HIV and metabolic dysfunction-associated steatotic liver disease: a prospective cohort study 糖尿病与HIV合并代谢功能障碍相关脂肪性肝病成人患者发生显著肝纤维化的风险：一项前瞻性队列研究 Win Min Han and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag053, https://doi.org/10.1093/jac/dkag053 34 A pharmacovigilance analysis of carbapenem-related utilizing the FDA adverse event reporting system (FAERS) database from 2013 to 2025 基于美国食品药品监督管理局不良事件报告系统（FAERS）数据库2013 - 2025年数据的碳青霉烯类相关药物警戒分析 Connor Frey and Parham Elmi Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag060, https://doi.org/10.1093/jac/dkag060 35 Effects of extracorporeal membrane oxygenation on the pharmacokinetics and tissue penetration rates of vancomycin and linezolid: data from Landrace pigs 体外膜肺氧合对万古霉素和利奈唑胺药代动力学及组织穿透率的影响：来自长白猪的数据 Huifang Zhang and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag063, https://doi.org/10.1093/jac/dkag063 36 Switching to bictegravir/emtricitabine/tenofovir alafenamide in people with HIV and prior resistance mutations. Data from the Italian ARCA cohort: the BIC-BARRIER study. B/F/TAF switch: mutations and outcomes 在既往存在耐药突变的人类免疫缺陷病毒（HIV）感染者中换用比克替拉韦/恩曲他滨/丙酚替诺福韦治疗。来自意大利ARCA队列的数据：BIC-BARRIER研究。比克替拉韦/恩曲他滨/丙酚替诺福韦（B/F/TAF）换药方案：耐药突变与治疗结果 Laura Pezzati and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag035, https://doi.org/10.1093/jac/dkag035 37 A two-stage diagnostic model for discriminating and assessing risk of meropenem heteroresistance in Pseudomonas aeruginosa 用于鉴别和评估铜绿假单胞菌对美罗培南异质性耐药风险的二阶段诊断模型 Yali Fan and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag061, https://doi.org/10.1093/jac/dkag061 38 Microdialysis assessment of gentamicin for second-line antimicrobial prophylaxis in abdominal surgery 微透析评估庆大霉素在腹部手术中作为二线抗菌预防药物的效果 Quentin Saint-Genis and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag071, https://doi.org/10.1093/jac/dkag071 39 Genetic and clinical predictors of voriconazole pharmacokinetics and hepatotoxicity: focused on CYP2C19 normal and intermediate metabolizers 伏立康唑药代动力学及肝毒性的遗传和临床预测因素：聚焦于CYP2C19正常代谢型和中间代谢型 Hui Li and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag065, https://doi.org/10.1093/jac/dkag065 40 Stakeholder perspectives on the offer and acceptance of self-administration of outpatient parenteral antimicrobial therapy: a qualitative study 利益相关者对提供和接受门诊患者自行注射抗菌药物治疗的看法：一项定性研究 Hester H Stoorvogel and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag068, https://doi.org/10.1093/jac/dkag068 41 Is current guidance for cloxacillin prophylaxis dosages in hip and knee arthroplasty adequate? Evidence from a prospective Swedish cohort 当前髋关节和膝关节置换术中氯唑西林预防性用药剂量指南是否充分？来自一项前瞻性瑞典队列研究的证据 Katja Wallander and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag067, https://doi.org/10.1093/jac/dkag067 42 Effect of pretreatment HIV drug resistance on mortality, attrition and viral suppression in patients initiating antiretroviral therapy and genetic transmission network: an observational cohort study in Southwest China 治疗前HIV药物耐药性对开始接受抗逆转录病毒治疗患者的死亡率、失访率和病毒抑制率的影响以及遗传传播网络：中国西南地区一项观察性队列研究 Litai Qin and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag073, https://doi.org/10.1093/jac/dkag073 RESEARCH LETTER（研究快讯） 43 Varicella and varicella zoster virus meningoencephalitis in a diffuse large B-cell lymphoma patient after chimeric antigen receptor-T-cell therapy 嵌合抗原受体T细胞疗法后，弥漫性大B细胞淋巴瘤患者发生水痘及水痘-带状疱疹病毒脑膜脑炎 Yan Feng and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag041, https://doi.org/10.1093/jac/dkag041 44 The ‘double hit’ on dalbavancin pharmacokinetics: hypertriglyceridaemia and augmented renal clearance in a child with glycogen storage disease type Ib 糖原累积病Ib型患儿中，高甘油三酯血症和肾清除率增加对达巴万星药代动力学的“双重打击” Bianca Monti and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag028, https://doi.org/10.1093/jac/dkag028 45 Tn7860, a novel chromosomal pseudo-compound transposon carrying the OptrA gene in Enterococcus faecalis Tn7860，粪肠球菌中携带OptrA基因的一种新型染色体假复合转座子 Francesca Romana Massacci and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag046, https://doi.org/10.1093/jac/dkag046 46 HBV reactivation after switching to cabotegravir plus rilpivirine therapy among people living with HIV: do not forget the reservoir HIV感染者换用卡博特韦（cabotegravir）联合利匹韦林（rilpivirine）治疗后乙肝病毒再激活：切勿忽视病毒储存库 Rémi Rouget and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag050, https://doi.org/10.1093/jac/dkag050 47 An inoperable mediastinal infection involving vascular graft treated with weekly oritavancin as chronic suppressive therapy. A case report with pharmacokinetic data 一例涉及血管移植物的无法手术的纵隔感染，采用每周一次的奥利万星作为慢性抑制疗法。附药代动力学数据的病例报告 Pierangelo Chinello and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag013, https://doi.org/10.1093/jac/dkag013 48 Evaluation of the Carbapenemase Detection Kit (Colloidal Gold; Macro & Micro Test): a new immunochromatographic assay for rapid detection of carbapenemases in Enterobacterales 碳青霉烯酶检测试剂盒（胶体金法；宏基因与微基因检测法）评估：一种用于快速检测肠杆菌目细菌中碳青霉烯酶的新型免疫层析法 Hippolyte De Swardt and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag066, https://doi.org/10.1093/jac/dkag066 49 Cefalexin use in UK acute pyelonephritis practice: unaddressed challenges in dosing, breakpoints and clinical evidence 头孢氨苄在英国急性肾盂肾炎治疗中的应用：给药、断点和临床证据方面尚未解决的挑战 Stephen Hughes and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag051, https://doi.org/10.1093/jac/dkag051 LETTERS TO THE EDITOR（致编辑的信） 50 Comment on: Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy 评论：意大利米兰多西环素暴露后预防（DoxyPEP）使用者中用于治疗细菌性性传播感染的抗菌药物使用情况 Chris Kenyon Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag025, https://doi.org/10.1093/jac/dkag025 51 Possible increased risk of Epstein–Barr virus (EBV) infection and post-transplant lymphoproliferative disease (PTLD) in letermovir-exposed haematopoietic cell transplantation recipients: right-to-reply 来特莫韦暴露的造血细胞移植受者发生EB病毒（EBV）感染和移植后淋巴增殖性疾病（PTLD）的风险可能增加：答复权 Jose F Camargo and Anthony D Anderson Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag043, https://doi.org/10.1093/jac/dkag043 52 Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy—right-to-reply 意大利米兰市使用多西环素暴露后预防（DoxyPEP）人群中，用于治疗细菌性性传播感染的抗菌药物使用情况——答复权声明 Angelo Roberto Raccagni and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag026, https://doi.org/10.1093/jac/dkag026 53 Comment on: Artificial intelligence for improving decision-making in bacterial infection management 述评：人工智能在细菌感染管理决策中的优化作用 Daniele Roberto Giacobbe Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag078, https://doi.org/10.1093/jac/dkag078 CORRECTION（更正） 54 Correction to: Bayesian estimation of the prevalence of antimicrobial resistance: a mathematical modelling study 更正：抗菌药物耐药性流行率的贝叶斯估计：一项数学建模研究 Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkaf494, https://doi.org/10.1093/jac/dkaf494 55 Correction to: National representative survey of pretreatment HIV drug resistance in Colombia: analysis of antiretroviral resistance-associated mutations using next-generation sequencing 更正：哥伦比亚具有全国代表性的治疗前HIV耐药性调查：使用下一代测序技术分析抗逆转录病毒耐药相关突变 Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag057, https://doi.org/10.1093/jac/dkag057 Journal of Antimicrobial Chemotherapy Volume 81, Issue 4抗菌化疗杂志81卷 4期 https://academic.oup.com/jac/issue 50TH ANNIVERSARY COLLECTION（50周年纪念合集） GARROD LECTURE（加罗德讲座） 1 Garrod lecture: achieving the UNGA AMR mortality reduction goals 加罗德讲座：实现联合国大会抗菌药物耐药性死亡率降低目标 Ramanan Laxminarayan Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag082, https://doi.org/10.1093/jac/dkag082 REVIEW（综述） 2 25 years of improvement in mortality in invasive aspergillosis in haematology patients: will it be sustained or is it under threat? 侵袭性曲霉病血液病患者25年死亡率改善情况：这种改善能否持续，还是正受到威胁？ Johan A Maertens and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag077, https://doi.org/10.1093/jac/dkag077 3 A strategic discovery roadmap towards high-quality leads and drug development candidates for kinetoplastid diseases. Part 2: from molecule to confirmed hit 针对锥虫病的从高质量潜在客户和药物开发候选者出发的战略发现路线图。第二部分：从分子到确证活性分子 Sarah Hendrickx and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag110, https://doi.org/10.1093/jac/dkag110 VIRTUAL ROUNDTABLE（虚拟圆桌会议） 4 Diagnosis and risk factors for invasive mould disease—a round table discussion on directing antifungal therapy according to the available evidence 侵袭性霉菌病的诊断与危险因素——根据现有证据指导抗真菌治疗的圆桌讨论 Ana Alastruey-Izqueirdo and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag062, https://doi.org/10.1093/jac/dkag062 EDITORIALS, MESSAGES FROM THE OUTGOING AND INCOMING EDITORS-IN-CHIEF（社论、离任与就任主编寄语） 5 Message from the incoming Editor-in-Chief of JAC 《抗菌化疗杂志》就任主编寄语 Monica A Slavin Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkaf479, https://doi.org/10.1093/jac/dkaf479 6 Message from the outgoing Editor-in-Chief 离任主编寄语 J Peter Donnelly Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkaf480, https://doi.org/10.1093/jac/dkaf480 REVIEW（综述） 7 Experimental biofilm models for pharmacokinetic and pharmacodynamic investigations: bridging in vitro, ex vivo and in vivo systems 用于药代动力学和药效学研究的实验性生物膜模型：连接体外、离体和体内系统 Stephanie Supparitsch and Markus Zeitlinger Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag091, https://doi.org/10.1093/jac/dkag091 8 Antimicrobial therapy for infected necrotizing pancreatitis: microbiology, antimicrobial resistance and pharmacokinetics 感染性坏死性胰腺炎的抗菌治疗：微生物学、抗菌药物耐药性及药代动力学 Hannah S Pauw and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag092, https://doi.org/10.1093/jac/dkag092 9 Continuous linezolid infusion: the new way to dose, the old risks to fear 持续输注利奈唑胺：新的给药方式，仍需警惕旧有风险 Daniel Muñoz-Pichuante and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag100, https://doi.org/10.1093/jac/dkag100 10 Alignment of national standard treatment guidelines with WHO AWaRe recommendations for adult primary care infectious diseases: implications for antimicrobial stewardship 将国家标准治疗指南与世卫组织（WHO）针对成人初级保健传染病的“慎用、监测、备用”（AWaRe）推荐意见相统一：对抗菌药物管理的影响 Huda Arooj and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag099, https://doi.org/10.1093/jac/dkag099 SYSTEMATIC REVIEW（系统综述） 11 Healthcare providers’ experiences in caring for MDRO carriers with a focus on the moral dimensions of care: a systematic review 医疗服务提供者护理多重耐药菌（MDRO）携带者的经历——聚焦护理中的道德维度：一项系统综述 Carlijn Damsté and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag059, https://doi.org/10.1093/jac/dkag059 12 Extrapolation of oritavancin PK/PD targets to inform therapeutic drug monitoring: a systematic review 奥利他万星药代动力学/药效学目标的外推用以指导治疗药物监测：一项系统综述 Giammarco Baiardi and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag117, https://doi.org/10.1093/jac/dkag117 ORIGINAL RESEARCH（论著） 13 Beyond plasma: defining the translation value of epithelial lining fluid exposure profiles for the treatment of pneumonia 超越血浆：明确上皮衬里液暴露谱对肺炎治疗的转化价值 Yakun Fu and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkaf458, https://doi.org/10.1093/jac/dkaf458 14 Impact of loading dose β-lactam therapy on outcomes of KPC-producing Klebsiella pneumoniae bloodstream infections in non-ICU patients: a real world study 负荷剂量β-内酰胺类药物治疗非重症监护病房患者产KPC肺炎克雷伯菌血流感染的疗效影响：一项现实研究 Luisa Frallonardo and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag087, https://doi.org/10.1093/jac/dkag087 15 Rezafungin exhibits anti-biofilm properties against fungal biofilms in vitro 雷扎芬净在体外对真菌生物膜表现出抗生物膜特性 Hafsa Abduljalil and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag058, https://doi.org/10.1093/jac/dkag058 16 Vancomycin resistance predicts increased mortality in patients with Enterococcus faecium bloodstream infections: a six-year experience at a large tertiary care Italian hospital 万古霉素耐药性可预测屎肠球菌血流感染患者死亡率增加：意大利一家大型三级医院六年来的经验 Lucia Graziani and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag069, https://doi.org/10.1093/jac/dkag069 17 Fluoroquinolones and the risk of panic attacks: a systematic review and disproportionality analysis using individual case safety reports from the FDA Adverse Event Reporting System (FAERS) database 氟喹诺酮类药物与惊恐发作风险：基于美国食品药品监督管理局不良事件报告系统（FAERS）数据库中个体病例安全报告的系统综述和比例失衡分析 Keeirah Hiertika Raguram and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag083, https://doi.org/10.1093/jac/dkag083 18 Cefuroxime concentrations in facial artery musculomucosal flap, buccal submucosa, subcutaneous tissue, and plasma following bolus or continuous infusion in patients undergoing oral cancer resection: a randomized clinical microdialysis study 在接受口腔癌切除术的患者中，采用随机临床微透析研究，探究头孢呋辛在面动脉肌黏膜瓣、颊黏膜下层、皮下组织和血浆中的浓度（团注或持续输注后） Johanne Ravn Hansen and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag085, https://doi.org/10.1093/jac/dkag085 19 Infection point of care tests bridge the experience gap of antibiotic STOP decisions: clinicians versus students 感染即时检测可弥补抗生素停药决策方面的经验差距：临床医生与学生对比 Archit Singhal and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkaf486, https://doi.org/10.1093/jac/dkaf486 20 Functional analysis of a novel macrolide–lincosamide resistance gene erm(57) in Cutibacterium avidum 痤疮丙酸杆菌中一种新型大环内酯 - 林可酰胺类耐药基因erm(57)的功能分析 Juri Koizumi and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag029, https://doi.org/10.1093/jac/dkag029 21 HIV drug resistance amongst children and adolescents with viraemia in Lesotho and Tanzania: a nested analysis in the GIVE MOVE trial 莱索托和坦桑尼亚病毒血症儿童及青少年中的HIV耐药性：GIVE MOVE试验的嵌套分析 Christof Manuel Schönenberger and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag070, https://doi.org/10.1093/jac/dkag070 22 Identification and assessment of paediatric cefepime-induced neurotoxicity in a retrospective cohort of paediatric intensive care patients 在儿科重症监护患者回顾性队列中识别和评估儿科头孢吡肟诱导的神经毒性 Kathryn Pavia and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag075, https://doi.org/10.1093/jac/dkag075 23 Prioritization of adverse events related to integrase inhibitors and NNRTIs: a disproportionality analysis using data from the FAERS database 整合酶抑制剂和非核苷类逆转录酶抑制剂相关不良事件的优先级排序：基于FAERS数据库数据的比例失衡分析 Gao-yang Wang and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag074, https://doi.org/10.1093/jac/dkag074 24 Clinical and immunovirological status in children, adolescents and young adults with early-life-acquired HIV: a Spanish multi-cohort analysis since 2020 自2020年以来西班牙多队列分析中，儿童、青少年及青年时期感染HIV者的临床及免疫病毒学状态 Laura Tarancon-Diez and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag079, https://doi.org/10.1093/jac/dkag079 25 Population pharmacokinetics of meropenem in critically ill adult patients receiving extracorporeal membrane oxygenation—an ASAP ECMO study 接受体外膜肺氧合治疗的危重成年患者美罗培南的群体药代动力学——一项ASAP ECMO研究 Mohd H Abdul–Aziz and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag090, https://doi.org/10.1093/jac/dkag090 26 Evaluation of HIV-1 transmitted drug-resistance among subtypes circulating from 2022 to 2024 in Italy: a refined analysis through next-generation sequencing 2022年至2024年意大利流行HIV-1亚型间传播耐药性的评估：通过下一代测序技术进行的精细分析 Daniele Armenia and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag084, https://doi.org/10.1093/jac/dkag084 27 Characterization of efflux pump channel of florfenicol for resistance-enhancing variant RE-CmeABC in Campylobacter 耐药增强型变异体RE-CmeABC中氟苯尼考外排泵通道在弯曲菌中的特性研究 Hong Yao and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag047, https://doi.org/10.1093/jac/dkag047 28 Genomic characterization of colistin heteroresistance in Acinetobacter baumannii: Evidence for lpxD deletion and collateral sensitivity 鲍曼不动杆菌中黏菌素异质性耐药的基因组特征：lpxD缺失及附带敏感性的证据 Banu Sancak and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag076, https://doi.org/10.1093/jac/dkag076 29 Sustaining stewardship: longitudinal evaluation of an integrated antimicrobial programme in the ICU 持续管理：重症监护室（ICU）综合抗菌药物管理项目的纵向评估 Ashmitha Thomas and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag086, https://doi.org/10.1093/jac/dkag086 30 Global dissemination of optrA-mediated linezolid resistance in enterococci 利奈唑胺耐药性基因optrA介导的肠球菌在全球的传播 Jia Qi Beh and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag089, https://doi.org/10.1093/jac/dkag089 31 Predicting oral cephalosporin susceptibility in Escherichia coli blood isolates using parenteral cephalosporin susceptibility testing 利用肠外头孢菌素敏感性试验预测大肠杆菌血培养分离株对口服头孢菌素的敏感性 Tho H Pham and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag093, https://doi.org/10.1093/jac/dkag093 32 The pharmacodynamics of polymyxin B in Acinetobacter baumannii in murine thigh and lung infection models 在小鼠大腿和肺部感染模型中多粘菌素B对鲍曼不动杆菌的药效动力学研究 Sanne van den Berg and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag097, https://doi.org/10.1093/jac/dkag097 33 Genomic insights into the tmexCD-toprJ: plasmid-mediated evolution, dissemination and diversity in bacterial populations 关于tmexCD-toprJ的基因组见解：质粒介导的细菌群体进化、传播与多样性 Lilan Wan and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag107, https://doi.org/10.1093/jac/dkag107 34 Baseline resistance mutations and virological response to dolutegravir in treatment-naïve patients: a multicentre NGS study 初治患者基线耐药突变与多替拉韦病毒学应答：一项多中心下一代测序（NGS）研究 Alexy Inciarte and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag080, https://doi.org/10.1093/jac/dkag080 35 Novel integrase mutations linked to genotypic DTG resistance in African non-B HIV-1 strains: the DTG RESIST study 非洲非B型HIV-1毒株中与多替拉韦（DTG）基因型耐药相关的新型整合酶突变：DTG耐药研究 Nuri Han and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag088, https://doi.org/10.1093/jac/dkag088 36 Pharmacological evaluation of an ex vivo cervicovaginal HIV prevention model 体外宫颈阴道HIV预防模型的药理学评估 Lindsey B Collins and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag103, https://doi.org/10.1093/jac/dkag103 37 The magnitude of the pharmacodynamic index for NOSO-502: pathogen clearance, emergence of resistance and human dose predictions NOSO-502药效学指数的幅度：病原体清除、耐药性出现和人体剂量预测 Sanne van den Berg and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag106, https://doi.org/10.1093/jac/dkag106 38 Temocillin: a therapeutic alternative in bone and joint infections due to third generation cephalosporin-resistant Enterobacterales? 替莫西林：治疗第三代头孢菌素耐药肠杆菌目引起的骨关节感染的一种替代疗法？ Louise Piquart and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag105, https://doi.org/10.1093/jac/dkag105 39 Metallo-β-lactamase–producing Enterobacterales: cyanide-containing efflux pump inhibitors as potential dual-activity inhibitors 产金属β-内酰胺酶的肠杆菌科细菌：含氰化物的外排泵抑制剂作为潜在的双活性抑制剂 Otávio Hallal Ferreira Raro and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag122, https://doi.org/10.1093/jac/dkag122 40 Outer membrane vesicles transmit blaNDM-5 and package metallo-β-lactamases to promote antibiotic resistance in Escherichia coli 外膜囊泡传递blaNDM-5并包装金属β-内酰胺酶以促进大肠杆菌的抗生素耐药性 Ting-Yin Lu and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag123, https://doi.org/10.1093/jac/dkag123 41 Characterization of a ST412-K57 colistin-resistant hypervirulent Klebsiella pneumoniae strain of chicken origin 一株鸡源ST412-K57多粘菌素耐药高毒力肺炎克雷伯菌的特征分析 Qiu Xu and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag114, https://doi.org/10.1093/jac/dkag114 42 Olorofim in combination with azole antifungals: results from the Phase 2 salvage therapy study 奥罗芬明与唑类抗真菌药联合使用：2期挽救治疗研究结果 Johan Maertens and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag118, https://doi.org/10.1093/jac/dkag118 RESEARCH LETTER（研究快讯） 43 Infant HIV transmission despite maternal viral suppression: a case of post-weaning seroconversion 母体病毒得到抑制，婴儿仍发生HIV传播：一例断奶后血清转阳病例 Shadia Nakalema and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag072, https://doi.org/10.1093/jac/dkag072 44 Urinary antigen–negative Legionella pneumonia in critically ill patients: value of systematic molecular testing for optimal antimicrobial therapy 危重患者中尿抗原阴性军团菌肺炎：系统分子检测在优化抗菌治疗中的价值 Livia Foglia Manzillo and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag101, https://doi.org/10.1093/jac/dkag101 45 Contribution of SHV-1 overexpression to carbapenem resistance in a Klebsiella pneumoniae clinical isolate SHV-1过表达对某株肺炎克雷伯菌临床分离株碳青霉烯类抗生素耐药性的影响 Céline Plainvert and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag108, https://doi.org/10.1093/jac/dkag108 LETTER TO THE EDITOR（致编辑的信） 46 Comment on: Possible increased risk of Epstein–Barr virus (EBV) infection and posttransplant lymphoproliferative disease (PTLD) in letermovir-exposed haematopoietic cell transplantation recipients 评论：接受莱特莫韦治疗的造血细胞移植受者中，EB病毒（EBV）感染和移植后淋巴增殖性疾病（PTLD）的风险可能增加 Jan Styczynski Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag042, https://doi.org/10.1093/jac/dkag042 47 Comment on: Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis users in Milan, Italy 评论：意大利米兰地区使用多西环素暴露后预防措施人群中针对细菌性性传播感染的抗菌药物使用情况 Luca Bortolani and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag023, https://doi.org/10.1093/jac/dkag023 48 Retrospective analysis of pharmacological therapeutic monitoring of caspofungin in patients undergoing continuous renal replacement therapy using polyacrylonitrile membranes—right to reply 使用聚丙烯腈膜进行连续肾脏替代治疗的患者中卡泊芬净药物治疗监测的回顾性分析——答复权 Antoine Hérault and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag095, https://doi.org/10.1093/jac/dkag095 49 Comment on: Temocillin versus other intravenous beta-lactams for urinary tract infections caused by third-generation cephalosporin-resistant Enterobacterales: a multicentre retrospective matched-cohort study 评论：替莫西林与其他静脉注射β-内酰胺类抗生素治疗第三代头孢菌素耐药肠杆菌目引起的尿路感染：一项多中心回顾性匹配队列研究 Shanshan Ru and Yingzhe Zhang Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag096, https://doi.org/10.1093/jac/dkag096 50 Comment on: Long-acting glycopeptides: what are the barriers to access in patients who need them most, and how can they be overcome? 评论：长效糖肽类抗生素：对于最需要它们的患者，获取的障碍是什么，如何克服？ Marco Bongiovanni Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag102, https://doi.org/10.1093/jac/dkag102 51 Comment on ‘Retrospective analysis of pharmacological therapeutic monitoring of caspofungin in patients undergoing continuous renal replacement therapy using polyacrylonitrile membranes’ 评论：“对使用聚丙烯腈膜进行连续肾脏替代治疗的患者中卡泊芬净的药理学治疗监测的回顾性分析” Julien Massol and Frédéric Baud Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag094, https://doi.org/10.1093/jac/dkag094 52 Comment on: ‘Epidemiology and treatment of endocarditis secondary to Enterobacterales other than Serratia spp’ 对“除塞拉蒂亚属（Serratia spp）外肠杆菌目所致心内膜炎的流行病学和治疗”的评论 Gianpiero Tebano and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag098, https://doi.org/10.1093/jac/dkag098 53 ‘Comparing serotype coverage of pneumococcal vaccines with PCV21 (V116), a new 21-valent conjugate pneumococcal vaccine, and the epidemiology of its eight unique Streptococcus pneumoniae serotypes (15A, 15C, 16F, 23A, 23B, 24F, 31 and 35B) causing invasive pneumococcal disease in adult patients in Canada: SAVE study, 2018–2021-right-to-reply’ “比较肺炎球菌疫苗的血清型覆盖率——PCV21（V116，一种新型21价结合肺炎球菌疫苗）与加拿大成人患者中导致侵袭性肺炎球菌疾病的其8种独特肺炎链球菌血清型（15A、15C、16F、23A、23B、24F、31和35B）的流行病学：SAVE研究，2018 - 2021年——回应” John J Schellenberg and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag126, https://doi.org/10.1093/jac/dkag126 54 Comment on: Antagonistic in vitro interaction between olorofim and voriconazole against Aspergillus fumigatus 评论：奥罗芬明与伏立康唑对烟曲霉的体外拮抗作用 Corinne Pinder and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag119, https://doi.org/10.1093/jac/dkag119 55 Epidemiology and treatment of endocarditis secondary to Enterobacterales other than Serratia spp.: right-to-reply 除塞氏杆菌属外肠杆菌科细菌所致心内膜炎的流行病学和治疗：回应 Sunish Shah and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag121, https://doi.org/10.1093/jac/dkag121 Journal of Antimicrobial Chemotherapy Volume 81, Issue 5抗菌化疗杂志81卷 5期 https://academic.oup.com/jac/issue 50TH ANNIVERSARY COLLECTION（50周年纪念合集） REVIEW（综述） 1 A strategic discovery roadmap towards high-quality leads and drug development candidates for kinetoplastid diseases. Part 1: setting the stage 针对动基体病的高质量先导化合物及药物开发候选物的战略发现路线图。第一部分：背景介绍 Sarah Hendrickx and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag109, https://doi.org/10.1093/jac/dkag109 REVIEW（综述） 2 Pathophysiology, risk factors and clinical management for polymyxin-associated acute kidney injury 多粘菌素相关急性肾损伤的病理生理学、危险因素及临床治疗 Simiao Zhao and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag132, https://doi.org/10.1093/jac/dkag132 SYSTEMATIC REVIEW（系统综述） 3 Definitions and rates of treatment failure in females with uncomplicated urinary tract infection: a systematic literature review 女性单纯性尿路感染治疗失败的定义及发生率：一项系统文献综述 Meghan E Luck and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag112, https://doi.org/10.1093/jac/dkag112 4 Therapeutic drug monitoring and the role of pharmacokinetics/pharmacodynamics in optimizing beta-lactam antibiotic dosing for deep-seated infections: a systematic review 在针对深部感染的β-内酰胺类抗生素优化给药方案中治疗药物监测以及药代动力学/药效学的作用：一项系统综述 Cassandra Vale and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag142, https://doi.org/10.1093/jac/dkag142 ORIGINAL RESEARCH（论著） 5 Optimizing cloxacillin prophylaxis in hip and knee arthroplasty based on population pharmacokinetics of unbound plasma concentrations 基于游离血浆浓度群体药代动力学优化髋关节和膝关节置换术中的氯唑西林预防用药方案 Gustaf Beijer and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag116, https://doi.org/10.1093/jac/dkag116 6 The tissue distribution and pharmacokinetics of [14C]-olorofim following intravenous dosing in the rat 大鼠静脉注射[14C]奥洛罗芬后的组织分布及药代动力学研究 Derek Law and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag120, https://doi.org/10.1093/jac/dkag120 7 Insights from the WHO Tricycle-aligned Fleming Fund EQASIA External Quality Assessment (EQA) programme detecting ESBL-, AmpC- and carbapenemase-producing Escherichia coli in South and South-East Asia 世界卫生组织三轮车项目（Tricycle）协同的弗莱明基金南亚和东南亚地区外部质量评估（EQASIA EQA）计划在检测南亚和东南亚地区产超广谱β-内酰胺酶（ESBL）、AmpC酶和碳青霉烯酶的大肠埃希菌方面的见解 Hiba Al-Mir and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag129, https://doi.org/10.1093/jac/dkag129 8 The plasma and intracellular exposure of intramuscularly administered long-acting cabotegravir and rilpivirine in people with HIV HIV感染者肌内注射长效卡博特韦和利匹韦林后的血浆及细胞内暴露情况 Micol Ferrara and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag113, https://doi.org/10.1093/jac/dkag113 9 In vitro synergistic activity of minocycline and biapenem against cefiderocol-resistant New Delhi metallo-β-lactamase-producing Enterobacterales 米诺环素与比阿培南在体外对产新德里金属β-内酰胺酶且对头孢地尔耐药的肠杆菌科细菌的协同作用 Takashi Okanda and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag128, https://doi.org/10.1093/jac/dkag128 10 Mortality risk of ESBL producers in Escherichia coli bacteraemia: a comprehensive analysis using the PROBAC cohort 产超广谱β-内酰胺酶大肠埃希菌菌血症的死亡风险：基于PROBAC队列的综合分析 Paula Olivares-Navarro and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag130, https://doi.org/10.1093/jac/dkag130 11 Molecular mechanism of envZ regulating β-lactam antibiotic resistance and virulence in Escherichia coli EnvZ调控大肠埃希菌β-内酰胺类抗生素耐药性及毒力的分子机制 Kun Yang and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag104, https://doi.org/10.1093/jac/dkag104 12 In vitro activity of amoxicillin combined with oral cephalosporins against endocarditis-associated E. faecalis clinical isolates 阿莫西林联合口服头孢菌素针对心内膜炎相关粪肠球菌临床分离株的体外活性 David Luque Paz and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag127, https://doi.org/10.1093/jac/dkag127 13 Genome-wide association studies builds a predictive model and reveals novel resistance features for macrolide-resistant Bordetella pertussis 全基因组关联研究构建预测模型并揭示大环内酯类耐药百日咳鲍特菌的新耐药特征 Jialiang Chen and Guowei Liang Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag131, https://doi.org/10.1093/jac/dkag131 14 Real-world validation of a reduced-dose continuous infusion cefepime regimen: pharmacodynamic target attainment, efficacy and neurotoxicity 减量持续静脉输注头孢吡肟方案的实际应用验证：药效学目标达成情况、疗效及神经毒性 Kieffer Korvin and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag138, https://doi.org/10.1093/jac/dkag138 15 Cross-species and cross-border spread of aph(3′)-ia-mediated neomycin resistance in Escherichia coli from animals: a genomic perspective 从基因组角度研究动物源大肠杆菌中aph(3′)-ia介导的新霉素耐药性的跨物种和跨国传播 Mattia Pirolo and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag143, https://doi.org/10.1093/jac/dkag143 16 Prevalence of cyp51A variants in a US collection of Aspergillus fumigatus clinical isolates and comparative analysis of their contribution to triazole antifungal resistance 美国烟曲霉临床分离株集合中cyp51A变异体的流行情况及其对三唑类抗真菌药物耐药性作用的比较分析 Luisa Fernanda Gómez Londoño and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag124, https://doi.org/10.1093/jac/dkag124 17 In vitro and in vivo activity of daptomycin plus ceftaroline for the treatment of experimental endocarditis due to Enterococcus faecalis with and without high-level aminoglycoside resistance 达托霉素联合头孢洛林对高水平氨基糖苷类耐药及非耐药粪肠球菌所致实验性心内膜炎的体内外疗效研究 María-Alexandra Cañas and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag136, https://doi.org/10.1093/jac/dkag136 18 Pharmacokinetics of a three-dose regimen of intramuscular benzathine penicillin G in pregnant women with syphilis 三剂苄星青霉素G肌内注射方案在妊娠期梅毒患者中的药代动力学研究 Eshetie Melese Birru and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag145, https://doi.org/10.1093/jac/dkag145 19 Cefiderocol resistance mediated by mutation of the miniconductance mechanosensitive channel MscM in Klebsiella oxytoca 由产气克雷伯菌中微小电导机械敏感通道MscM发生突变所介导的头孢地尔耐药性 Pia Turowski and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag147, https://doi.org/10.1093/jac/dkag147 20 The veterinary clinic backyard lawn used for relief walks of hospitalized dogs is a hotspot for OXA-type carbapenemases in multiple Enterobacterales 兽医诊所后院供住院犬只散步的草坪是多种肠杆菌科细菌中OXA型碳青霉烯酶的传播热点区域 Yvonne Spahr and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag144, https://doi.org/10.1093/jac/dkag144 21 Pharmacokinetics of cefazolin in bariatric surgery patients: a preoperative perspective 头孢唑林在减肥手术患者中的药代动力学：术前视角 Alexandra Porlier and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag150, https://doi.org/10.1093/jac/dkag150 RESEARCH LETTERS（研究快讯） 22 Plasmid-encoded FRI-10 carbapenemase harboured by non-Enterobacter species isolated from a wastewater sample in Tokyo, Japan 从日本东京废水样本中分离出的非肠杆菌科物种携带质粒编码的FRI-10碳青霉烯酶 Kou Murakami and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag133, https://doi.org/10.1093/jac/dkag133 23 Synergistic activity of cefepime/enmetazobactam with meropenem, piperacillin, piperacillin/tazobactam, cefiderocol and fosfomycin against Klebsiella pneumoniae carrying blaKPC allelic variants 头孢吡肟/恩美唑巴坦与美罗培南、哌拉西林、哌拉西林/他唑巴坦、西他沙星和磷霉素针对携带blaKPC等位基因变体的肺炎克雷伯菌的协同作用 Alice Crema and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag141, https://doi.org/10.1093/jac/dkag141 24 MRSA and carbapenem-resistant Acinetobacter baumannii on the fall: successful infection prevention and control in Chilean ICUs 耐甲氧西林金黄色葡萄球菌和耐碳青霉烯类鲍曼不动杆菌数量下降：智利重症监护病房感染预防与控制的成功案例 Patricio Ross and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag146, https://doi.org/10.1093/jac/dkag146 LETTER TO THE EDITOR（致编辑的信） 25 Comment on: Model-based assessment of VRC07-523LS dosing in infants through population pharmacokinetic–pharmacodynamic modelling in adults and infants 评论：基于模型的评估VRC07-523LS在婴儿中的给药剂量——基于成人和婴儿群体药代动力学-药效学模型 Wanhua Qiu Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag139, https://doi.org/10.1093/jac/dkag139 26 Comment on: Comparing serotype coverage of pneumococcal vaccines with PCV21 (V116), a new 21-valent conjugate pneumococcal vaccine, and the epidemiology of its eight unique Streptococcus pneumoniae serotypes (15A, 15C, 16F, 23A, 23B, 24F, 31 and 35B) causing invasive pneumococcal disease in adult patients in Canada: SAVE study, 2018–21 评论：比较含21种血清型的肺炎球菌疫苗PCV21（V116）（一种新型21价结合肺炎球菌疫苗）的血清型覆盖范围，以及2018 - 2021年SAVE研究中导致加拿大成年患者侵袭性肺炎球菌疾病的8种独特肺炎链球菌血清型（15A、15C、16F、23A、23B、24F、31和35B）的流行病学情况 Gokul Raj Pullagura and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag125, https://doi.org/10.1093/jac/dkag125 27 Comment on: Distinct population structure and genomic context of NarAB between broiler and human clinical Enterococcus isolates 评论：肉鸡源和人临床来源肠球菌分离株中NarAB的不同种群结构和基因组背景 Alex Wong Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag134, https://doi.org/10.1093/jac/dkag134 28 Distinct population structure and genomic context of narAB between broiler and human clinical Enterococcus isolates—authors’ response 肉鸡源和人临床来源肠球菌分离株中narAB的不同种群结构和基因组背景——作者回复 Jayanth Balakuntla and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag135, https://doi.org/10.1093/jac/dkag135 Journal of Antimicrobial Chemotherapy Volume 81, Issue 6抗菌化疗杂志81卷 6期 https://academic.oup.com/jac/issue 50TH ANNIVERSARY COLLECTION（50周年纪念合集） REVIEW（综述） 1 A strategic discovery roadmap towards high-quality leads and drug development candidates for kinetoplastid diseases. Part 3: from lead towards a drug development candidate 针对动基体疾病高质量先导化合物和药物开发候选物的战略发现路线图。第三部分：从先导化合物到药物开发候选物 Sarah Hendrickx and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag111, https://doi.org/10.1093/jac/dkag111 ORIGINAL RESEARCH（原创研究） 2 Population pharmacokinetics and probability of target attainment of tigecycline in critically ill children 危重患儿中替加环素（Tigecycline）的群体药代动力学及目标达成概率研究 Wenjuan Hu and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag156, https://doi.org/10.1093/jac/dkag156 3 Phenotypic and genotypic characterization of HMB-3, a metallo-beta-lactamase from Pseudomonas asiatica 假单胞菌属亚洲种（Pseudomonas asiatica）中金属β-内酰胺酶HMB-3的表型和基因型特征 Jacqueline Findlay and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag148, https://doi.org/10.1093/jac/dkag148 4 Early adequate linezolid concentrations and clinical outcomes in confirmed Gram-positive infections: the role of therapeutic drug monitoring 确诊的革兰氏阳性菌感染中早期达到适宜利奈唑胺浓度与临床预后的关系：治疗药物监测的作用 Daniel Fresán and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag137, https://doi.org/10.1093/jac/dkag137 5 Monte Carlo simulations identify suboptimal PK/PD target attainment with standard maribavir dosing 蒙特卡洛模拟表明标准剂量马立巴韦的药动学/药效学靶标达成情况欠佳 Yeleen Fromage and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag153, https://doi.org/10.1093/jac/dkag153 6 Exploring the pharmacokinetic mechanisms that affect bictegravir exposure during pregnancy 探究妊娠期间影响比克替拉韦暴露的药代动力学机制 L van der Wekken-Pas and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag159, https://doi.org/10.1093/jac/dkag159 7 Artificial intelligence for analysing antibiotic use: an exploratory study in a tertiary care paediatric hospital in Italy 人工智能用于分析抗生素使用情况：意大利一家三级儿科医院的探索性研究 Elio Castagnola and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag162, https://doi.org/10.1093/jac/dkag162 8 Antimicrobial activity of aztreonam–avibactam against KPC variant-producing Klebsiella pneumoniae with ceftazidime–avibactam resistance 氨曲南-阿维巴坦对产KPC变异体且对头孢他啶-阿维巴坦耐药的肺炎克雷伯菌的抗菌活性 Jingchun Kong and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag152, https://doi.org/10.1093/jac/dkag152 9 Highly transformable Haemophilus influenzae as a potential amplifier of quinolone resistance dissemination 高转化型流感嗜血杆菌作为喹诺酮耐药性传播的潜在放大器 Takeaki Wajima and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag160, https://doi.org/10.1093/jac/dkag160 10 Comparative nephrotoxicity of polymyxin B versus colistin: evidence from ensemble learning and propensity score matching 多黏菌素B与黏菌素的肾毒性比较：来自集成学习和倾向评分匹配的证据 Murat Özdede and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag044, https://doi.org/10.1093/jac/dkag044 11 Emulating a target trial of early compared with late initiation of appropriate antibiotic therapy for hospital-acquired monobacterial Gram-negative bloodstream infections 模拟医院获得性单菌革兰氏阴性菌血流感染早期与晚期开始恰当抗生素治疗的对照试验 Abdullah T Aslan and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag161, https://doi.org/10.1093/jac/dkag161 12 Flufenamic acid resensitizes MRSA to gentamicin through synergistic ion modulation 氟苯尼考通过协同离子调节使MRSA对庆大霉素重新敏感 Xiaomin Ren and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag154, https://doi.org/10.1093/jac/dkag154 13 Description of OXA-244 carbapenemase-producing Escherichia coli in farm animals in The Netherlands, 2024 2024年荷兰农场动物中OXA-244碳青霉烯酶产大肠杆菌的描述 K T Veldman and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag155, https://doi.org/10.1093/jac/dkag155 14 Clinical outcomes of beta-bactam monotherapy versus beta-lactam plus azithromycin in hospitalized patients with community-acquired pneumoniae β-内酰胺类单药治疗与β-内酰胺类联合阿奇霉素治疗社区获得性肺炎住院患者的临床预后比较 Ilona Zhygalova Zhygalova and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag158, https://doi.org/10.1093/jac/dkag158 15 ‘Leaving no stones unturned’: up to 10 years results on the effectiveness, tolerability and metabolic safety of dolutegravir+lamivudine (DTG+3TC) as a switch regimen in the ODOACRE cohort "不遗余力"：ODOACRE队列中多替拉韦+拉米夫定（DTG+3TC）作为转换方案长达10年的有效性、耐受性及代谢安全性结果 Arturo Ciccullo and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag172, https://doi.org/10.1093/jac/dkag172 16 Evaluation of a novel lateral flow immunochromatographic assay, Certest ResisCheck® Carbapenemases, for the rapid detection and differentiation of carbapenemase in Gram-negative bacteria from bacterial culture 新型侧向流免疫层析检测试剂Certest ResisCheck® Carbapenemases用于革兰氏阴性菌培养物中碳青霉烯酶快速检测与鉴别的评估 Laura Monge-Olivares and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag149, https://doi.org/10.1093/jac/dkag149 17 Temocillin efficacy and emergence of resistance in Enterobacter cloacae Complex in a murine peritonitis model 替莫西林对产气肠杆菌复合群的疗效及耐药性演变：小鼠腹膜炎模型研究 N Alanbari and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag151, https://doi.org/10.1093/jac/dkag151 18 Temporal association between aerosolized colistin use and colistin resistance in the ICU: a time-series analysis ICU中雾化粘菌素使用与粘菌素耐药之间的时间关联：一项时间序列分析 Weechang Kang and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag169, https://doi.org/10.1093/jac/dkag169 19 Can antimicrobial stewardship programmes be implemented during an armed conflict? A retrospective interventional cohort study 武装冲突期间能否实施抗菌药物管理计划？一项回顾性干预性队列研究 Hailie D Uren and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag115, https://doi.org/10.1093/jac/dkag115 20 Voriconazole therapy and CYP2C19 phenotype: identifying patients who may need alternative antifungal therapy 伏立康唑治疗与CYP2C19表型：识别可能需要替代抗真菌治疗的患者 Eman Wehbe and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag168, https://doi.org/10.1093/jac/dkag168 21 Impact of cardiopulmonary bypass on cefuroxime plasma and interstitial tissue concentrations in patients undergoing cardiac bypass surgery—a prospective controlled clinical trial 体外循环对心脏旁路手术患者头孢呋辛血浆及组织间质浓度的影响——一项前瞻性对照临床试验 Stefanie Nothofer and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag171, https://doi.org/10.1093/jac/dkag171 22 Population pharmacokinetic analysis and dosing regimen optimization of eravacycline in critically ill patients with carbapenem-resistant Acinetobacter baumannii pneumonia 对碳青霉烯耐药鲍曼不动杆菌肺炎危重患者中埃拉环素的药代动力学分析及给药方案优化 Luqi Lou and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag178, https://doi.org/10.1093/jac/dkag178 23 Durability and mechanistic performance of aztreonam/avibactam versus aztreonam plus ceftazidime/avibactam against Stenotrophomonas maltophilia complex 氨曲南/阿维巴坦与氨曲南联合头孢他啶/阿维巴坦对抗嗜麦芽窄食单胞菌复合群的耐久性和机制性能比较 Ashlan J Kunz Coyne and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag177, https://doi.org/10.1093/jac/dkag177 24 High-dose daptomycin for the treatment of invasive infections due to Enterococcus faecalis isolates with intermediate susceptibility 高剂量达托霉素治疗粪肠球菌中介敏感株所致侵袭性感染的疗效 Sidney Drake and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag179, https://doi.org/10.1093/jac/dkag179 25 Updated mapping of Plasmodium falciparum kelch13 gene polymorphisms in Madagascar, 2024 2024年马达加斯加恶性疟原虫kelch13基因多态性的最新图谱更新 Camille Roesch and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag181, https://doi.org/10.1093/jac/dkag181 26 Efficacy of ceftazidime/avibactam against 10 clinical isolates of Pseudomonas aeruginosa in icodextrin-based peritoneal dialysis solution and patient-derived dialysate 头孢他啶/阿维巴坦针对icodextrin基腹膜透析液及患者来源透析液中10株铜绿假单胞菌临床分离株的抗菌活性 Stephanie Supparitsch and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag185, https://doi.org/10.1093/jac/dkag185 27 Cefiderocol activity against multidrug-resistant isolates from the PERSEUS study: relationship between cefiderocol minimum inhibitory concentration and clinical outcomes 头孢德罗对PERSEUS研究中多重耐药分离株的抗菌活性：头孢德罗最低抑菌浓度与临床预后之间的关系 Rafael Cantón and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag164, https://doi.org/10.1093/jac/dkag164 28 Class 1 DISARM system in restriction of conjugative carbapenemase-encoding plasmids in Klebsiella pneumoniae sequence type 23 1类DISARM系统对肺炎克雷伯菌ST23中接合型碳青霉烯酶编码质粒的限制作用 Qingqing Du and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag167, https://doi.org/10.1093/jac/dkag167 29 Acute kidney injury following amikacin therapy: a retrospective cohort study 阿米卡星治疗后急性肾损伤：一项回顾性队列研究 Iris Zohar and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag188, https://doi.org/10.1093/jac/dkag188 30 Performance of EUCAST disc diffusion and supplementary methods to detect reduced susceptibility to linezolid in enterococci— the NordicAST LRE-study EUCAST纸片扩散法及补充方法检测肠球菌利奈唑胺低敏感性的表现——NordicAST LRE研究 Bjørg Christina Haldorsen and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag174, https://doi.org/10.1093/jac/dkag174 31 In vitro exposure to non-antipseudomonal antibiotics (NAPA) induces Pseudomonas aeruginosa resistance to antipseudomonal antibiotics (APA) 体外暴露于非抗假单胞菌抗生素（NAPA）可诱导铜绿假单胞菌对抗假单胞菌抗生素（APA）产生耐药性 David Lasry and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag182, https://doi.org/10.1093/jac/dkag182 32 Sub-inhibitory polyether ionophores enhance resistance plasmid transfer and transiently perturb the broiler gut resistome 亚抑制浓度的聚醚离子载体可促进耐药质粒转移并暂时扰乱肉鸡肠道耐药组 Jingyue Yang and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag190, https://doi.org/10.1093/jac/dkag190 33 Influence of a putative TonB-dependent receptor on cefiderocol susceptibility in clinical Enterobacter hormaechei isolates 推测的TonB依赖性受体对临床肠杆菌hormaechei分离株中头孢地尔敏感性的影响 Pia Turowski and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag193, https://doi.org/10.1093/jac/dkag193 RESEARCH LETTERS（研究快报） 34 Early bictegravir failure and emergence of R263K-mediated class-wide HIV integrase inhibitors resistance linked to over-the-counter supplement use 比克替拉韦早期治疗失败与R263K介导的与非处方补充剂使用相关的全类HIV整合酶抑制剂耐药的出现 Elisa Minacori and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag157, https://doi.org/10.1093/jac/dkag157 35 Environmental benefits of switching from intravenous to oral administration of ciprofloxacin 环丙沙星从静脉给药转换为口服给药的环境效益 Nicolas De Jaegher and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag163, https://doi.org/10.1093/jac/dkag163 36 Macrolide resistance via 23S rRNA gene mutation in Corynebacterium ulcerans 白喉棒状杆菌通过23S rRNA基因突变介导的大环内酯类耐药 Chiara Crestani and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag166, https://doi.org/10.1093/jac/dkag166 37 Prosthesis-associated Burkholderia cepacia complex infection managed with sequential directed therapy including ceftolozane/tazobactam 采用包括头孢妥仑/他唑巴坦在内的序贯导向疗法治疗假体相关洋葱伯克霍尔德菌复合感染 Elia Asensi-Díaz and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag165, https://doi.org/10.1093/jac/dkag165 38 Drug interactions and kidney safety of bictegravir/emtricitabine/tenofovir alafenamide in kidney transplant recipients with HIV: an interventional pilot study 比克替拉韦/恩曲他滨/丙酚替诺福韦在合并HIV的肾移植受者中的药物相互作用及肾脏安全性：一项干预性 pilot 研究 Thomas Stehlé and others Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag176, https://doi.org/10.1093/jac/dkag176 39 Harmonizing antimicrobial susceptibility testing: a comparison of CLSI and EUCAST categorizations 抗菌药物敏感性试验的协调：CLSI与EUCAST分类法的比较 Eric Farfour and Marie Lavollay Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag081, https://doi.org/10.1093/jac/dkag081 LETTER TO THE EDITOR（致编辑的信） 40 Comment on: Impact of loading dose β-lactam therapy on outcomes of KPC-producing Klebsiella pneumoniae bloodstream infections in non-ICU patients: a real world study 对"负荷剂量β-内酰胺类治疗对非ICU患者产KPC肺炎克雷伯菌血流感染结局的影响：一项现实研究"的评论 Xuefeng Yu Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag173, https://doi.org/10.1093/jac/dkag173 41 Comment on: ‘Cooperation between HIV-1 integrase natural polymorphism K156N and 3′PPT mutations in dolutegravir monotherapy failure’ 评论："HIV-1整合酶天然多态性K156N与3′PPT突变在多替拉韦单药治疗失败中的协同作用" Muhammad Ifham Hanif and Mentari Maratus Sholihah Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag175, https://doi.org/10.1093/jac/dkag175

2026-06-07

·米内网

8个首仿获批，9个品种获批新适应症，5个1类新药、16个改良型新药报产，这款吸入剂申报厂家最多

摘要 abstract 2026年5月，5个1类新药、16个改良型新药申请上市；121个品种按新分类仿制申请申报，其中19个品种暂无企业过评，瑞维那新吸入溶液申报企业最多，江西施美药业、辰欣药业的仿制申报品种数最多，均有3个；12个存量品种有企业申报一致性评价；8个1类新药首次获批，9个品种获批新适应症，8个品种首家过评，8个品种为首仿。创新药品种上市申请情况 2026年5月有5个1类新药申请上市，化学药有2个、生物制品有3个。 2026年5月创新药上市申请承办情况改良型新药品种上市申请情况 2026年5月有16个改良型新药品种的上市申请获CDE承办，涵盖新剂型、新适应症、新复方制剂以及新处方工艺。 2026年5月改良型新药上市申请承办情况一致性评价申请情况 2026年5月，121个品种按新分类仿制申请获CDE承办，其中19个品种暂无企业过评。瑞维那新吸入溶液申报企业最多，有6家。江西施美药业、辰欣药业申报品种数最多，均有3个。 2026年5月一致性评价申请情况(新分类仿制申请) 2026年5月，12个存量品种的一致性评价补充申请获CDE承办，盐酸头孢卡品酯片首次有企业申报。 2026年5月一致性评价申请情况(存量品种) 获批情况 2026年5月有8个1类新药首次获批上市、9个品种获批新适应症、1个品种有新剂型获批。 242个品种按新分类仿制申请获批并视同过评，21个品种按存量品种一致性评价补充申请过评，其中8个品种为首家过评。阿贝西利片、布立西坦注射液、甲磺酸沙非胺片、间苯三酚口崩片(Ⅱ)、利多卡因丁卡因乳膏、马立巴韦片、匹伐他汀钙口崩片、西尼莫德片等8个品种为首仿品种。 2026年5月主要注册类型品种获批情况数据来源：米内网中国申报进度数据库（MED）、CDE、NMPA；相关统计字段按药品名称统计，申报企业数按主申报企业统计，时间截至2026年5月31日；获批品种按NMPA批件发布时间统计；药物作用靶点以及适应症整理自公开资料；首仿品种指中国内地首仿品种。免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

100 项与马立巴韦相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D04859	马立巴韦	J05AX10	DB06234

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
巨细胞病毒感染	美国	Takeda Pharmaceuticals U.S.A., Inc.	2021-11-23

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
巨细胞病毒血症	临床3期	奥地利	Shire Plc	2017-04-14
巨细胞病毒血症	临床3期	加拿大	Shire Plc	2017-04-14
巨细胞病毒血症	临床3期	克罗地亚	Shire Plc	2017-04-14
巨细胞病毒血症	临床3期	捷克	Shire Plc	2017-04-14
巨细胞病毒血症	临床3期	希腊	Shire Plc	2017-04-14
巨细胞病毒血症	临床3期	匈牙利	Shire Plc	2017-04-14
巨细胞病毒血症	临床3期	意大利	Shire Plc	2017-04-14
巨细胞病毒血症	临床3期	新西兰	Shire Plc	2017-04-14
巨细胞病毒血症	临床3期	波兰	Shire Plc	2017-04-14
巨细胞病毒血症	临床3期	俄罗斯	Shire Plc	2017-04-14

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06034925 (Maribavir IIR, CTgov)	临床4期	巨细胞病毒感染 \| 移植并发症	70	valganciclovir (Control)	壓築顧願築觸範鏇鹹鏇 = 鏇製壓夢鑰蓋觸襯製憲繭壓製淵衊襯願範顧膚 (窪壓憲憲獵蓋遞醖醖鏇, 觸窪範獵淵鹹觸窪鏇淵 ~ 鹹醖構簾鏇淵膚膚膚夢) 更多	-	2026-04-30
NCT06034925 (Maribavir IIR, CTgov)	临床4期	巨细胞病毒感染 \| 移植并发症	70	Maribavir (Intervention)	壓築顧願築觸範鏇鹹鏇 = 艱艱築鹽廠築糧觸獵鏇繭壓製淵衊襯願範顧膚 (窪壓憲憲獵蓋遞醖醖鏇, 淵獵壓繭範鏇獵簾廠遞 ~ 觸製鏇齋衊夢糧膚糧淵) 更多	-	2026-04-30
ASH2025	N/A	巨细胞病毒感染	62	Maribavir 400 mg BID	築構鏇繭壓觸蓋鏇壓繭(製獵選窪廠顧範蓋憲齋) = 願憲願衊憲築齋窪網鹹鹹衊繭糧餘壓構夢觸獵 (淵齋夢範繭糧簾鑰襯醖 ) 更多	积极	2025-12-06
ASH2025	N/A	巨细胞病毒感染	62	Other first-line antiviral therapies	築構鏇繭壓觸蓋鏇壓繭(製獵選窪廠顧範蓋憲齋) = 艱範範構廠鹹衊鬱製夢鹹衊繭糧餘壓構夢觸獵 (淵齋夢範繭糧簾鑰襯醖 ) 更多	积极	2025-12-06
ASH2025	N/A	巨细胞病毒血症 \| 巨细胞病毒感染	57	Maribavir	製壓膚醖鹹蓋願壓餘齋(積廠顧鑰醖襯齋齋艱鹽) = grade 1 dysgeusia (n=4) and grade 2 myelosuppression (n=2) 鏇襯獵顧繭選觸積膚願 (窪憲衊廠蓋鑰觸顧範糧 ) 更多	积极	2025-12-06
NCT02931539 (Pubmed \| Expert Rev Anti Infect Ther)	临床3期	巨细胞病毒感染	-	Valganciclovir (VGCV)	淵膚構夢醖衊選構淵鏇(遞製齋築衊夢糧淵範鑰) = decreasing by 17.86% 觸築構淵齋鏇廠衊獵餘 (製衊選夢構壓蓋願壓餘 ) 更多	积极	2025-06-27
NCT02931539 (Pubmed \| Expert Rev Anti Infect Ther)	临床3期	巨细胞病毒感染	-	Maribavir (MBV)		积极	2025-06-27
NCT02931539 (SOLSTICE, Pubmed \| J Heart Lung Transplant)	临床3期	巨细胞病毒感染	211	Maribavir 400 mg twice daily	醖餘獵鬱窪選鬱憲鑰築(淵衊築齋淵顧製醖膚願) = 餘鑰鑰網觸淵窪夢窪醖構鹽糧窪艱襯顧繭範願 (壓衊構廠鑰網網襯鬱鏇 )	积极	2025-06-01
NCT02931539 (SOLSTICE, Pubmed \| J Heart Lung Transplant)	临床3期	巨细胞病毒感染	211	Investigator-assigned therapy (IAT)	醖餘獵鬱窪選鬱憲鑰築(淵衊築齋淵顧製醖膚願) = 網網製衊鹽憲獵艱範憲構鹽糧窪艱襯顧繭範願 (壓衊構廠鑰網網襯鬱鏇 )	积极	2025-06-01
IDWP EBMT (EHA2025)	N/A	巨细胞病毒感染	63	Maribavir	廠選遞蓋網餘艱鹹遞壓(餘願繭醖遞觸蓋積觸廠) = occurred after 14 courses; and in 2/14 a CMV end-organ disease (EOD) developed: 1 GID and 1 pneumonia 簾壓獵簾鬱夢選顧夢網 (夢鏇構鹹鏇鬱壓觸製築 ) 更多	积极	2025-05-14
NCT05918822 (CTgov)	临床1期	-	32	Maribavir+Rabeprazole	鬱選積簾淵膚齋襯餘齋(艱鬱齋鑰繭夢艱窪壓憲) = 夢獵願膚繭憲糧顧願壓襯襯蓋廠夢窪鬱築廠憲 (鑰鹹襯廠鏇蓋簾衊構艱, 49.9) 更多	-	2024-09-26
NCT05137717 (CTgov)	临床3期	巨细胞病毒感染	41	Maribavir	觸窪鬱觸遞齋襯遞鑰淵 = 鬱築遞獵遞簾襯壓餘繭繭齋築餘鬱繭範憲網窪 (廠築鑰蓋鬱構築簾蓋淵, 觸齋範蓋繭獵夢觸膚蓋 ~ 齋簾鹽憲鹹簾鹹製遞艱) 更多	-	2024-07-09
EHA2024	N/A	外周干细胞移植	12	Maribavir 400 mg twice daily	鏇築鏇餘獵鬱艱積蓋壓(鏇構選鑰選獵壓鏇鏇齋) = 願構醖築繭顧製壓遞糧繭艱鹽醖選壓鹽網構廠 (淵鑰糧範製繭簾憲壓簾, 100 ~ 1864500)	积极	2024-05-14
NCT02927067 (AURORA, Pubmed \| Clin Infect Dis)	临床3期	巨细胞病毒感染	-	Valganciclovir (dose-adjusted for renal clearance)	齋壓範膚衊鹽選餘鹽遞(築鑰獵觸積願襯窪餘壓) = 餘襯鹹鹽範鏇鹽遞壓顧餘廠襯醖願鬱鑰鑰範網 (廠壓構衊蓋繭獵餘鬱簾 ) 更多	不佳	2024-03-20